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Abstract 
Background: Pancreatic ductal adenocarcinoma (PDAC) comprises ~75% of all diagnosed cases 
of pancreatic cancer – the 4th leading cause of cancer death and a growing public health problem.  
The incidence of PDAC continues to increase while the overall 5-year survival rate remains <5%.  
This extremely poor prognosis is largely due to the absence of effective treatments and late 
diagnosis, making the identification and testing of new therapeutic targets and biomarkers a high 
priority.   
PDAC is marked by high expression of Tissue Factor (TF), the main physiologic trigger of blood 
coagulation. There are two forms of TF: full-length TF (flTF) that contains a transmembrane 
domain and alternatively spliced TF (asTF) that lacks a transmembrane domain and is secreted.  In 
malignant tissues, the function of TF is known to extend beyond clotting.  flTF triggers 
intracellular signaling via G protein-coupled protease-activated receptors (PARs), which leads to 
increased tumor growth predominantly by neoangiogenesis. It was later discovered that flTF 
expressed on cancer cells keeps β1-integrins in an inactive state and that FVIIa:TF binding releases 
this inhibition, rendering cancer cells more motile and responsive to integrin signaling.  In striking 
contrast to flTF, asTF binds and activates integrins promoting cancer cell proliferation, resistance 
to apoptosis, and angiogenesis, suggesting that the asTF-integrin signaling axis may represent a 
novel therapeutic target.    
Aim: To improve our understanding of the mechanisms regulating asTF-induced PDAC 
progression, examine circulating levels of asTF and assess the effectiveness of anti-asTF targeted 
therapeutics in hopes of improving PDAC treatment.   
ii
  
Methods: Tumor microarrays, PDAC specimens, and PDAC metastases were evaluated for asTF 
expression and/or monocyte infiltration.  PDAC cell lines were implanted in the pancreases of 
mice and in vivo imaging studies performed.  TF activity was measured using FXa chromogenic 
assay; TF levels were assessed using flow cytometry and ELISA.  Anti-asTF monoclonal antibody 
RabMab1 was co-implanted with Pt45P1 cells and monitored for tumor progression.    
 
Results/Conclusions: We report for the first time that asTF is expressed in human PDAC lesions 
exhibiting heavy monocyte infiltration, and demonstrate that asTF potentiates PDAC spread 
during early as well as late stages of disease.  asTF enhances the procoagulant potential of PDAC 
cells and cell derived microparticles. asTF-β1 integrin interactions render PDAC cells more motile, 
likely via competing with laminin for β1-integrin binding; RabMab1 fully inhibits asTF-
potentiated PDAC cell migration. Host-derived TF has no impact on the size of primary PDAC 
tumor, yet it contributes to tumor vascularization and, consequently, metastatic spread. When co-
implanted with RabMab1, Pt45P1 cells grow much smaller tumors with fewer monocytes and 
blood vessels that release less asTF into the circulation.  We also report that asTF at levels ≥0.2 
ng/mL occurs more frequently in the plasma of patients with PDAC compared to healthy subjects, 
and PDAC patients whose plasma asTF levels are ≥0.2 ng/mL have a significantly lower chance 
to qualify for tumor resection, irrespective of initial pre-surgical diagnostic evaluation. Thus, asTF 
may serve as marker of aggressive PDAC phenotype, and antibody-based targeting of asTF may 
comprise a novel therapeutic strategy to stem PDAC progression.  
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Chapter 1: Introduction 
In solving a problem of this sort, the grand thing is to be able to reason backwards.  
That is a very useful accomplishment, and a very easy one, but people do not 
practice it much. 
– Sherlock Holmes, in Sir Arthur Conan Doyle’s
A Study in Scarlet 
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1.1 The pancreas – a brief history 
The earliest known description of the pancreas is attributed to Herophilus of Chalcedon 
(300 B.C.), a Greek physician deemed to be one of the first human anatomists and adopter of the 
scientific method (1).  Despite Herophilus’s pioneering research on human anatomy, he received 
public criticism and was referred to as the ‘butcher’ of Alexandria – for his innumerable human 
dissections and gruesome vivisections performed before public audiences (2).  The name 
‘pancreas’ was later coined by Rufus (100 A.D.), another Greek physician, and etymologically 
translates as all flesh (pan: all, and kreas: flesh) – at the time the Greeks thought the pancreas was 
a fleshy cushion to protect the large blood vessels lying behind it (3).  It wasn’t until the 17th 
century that researchers discovered its glandular function.  In 1642, during the dissection of an 
executed murderer, Johann Georg Wirsüng, the prosector of Padua, described the main duct of the 
pancreas and to this day it bears his name (4). Wirsüng achieved historical immortality with his 
discovery, and at the same time it was his ruin: one year following his discovery he was murdered 
by a co-worker, the result of a quarrel over who was the first to truly discover the duct (5).  
Although Wirsüng is credited with the duct’s discovery, he never recognized the duct’s function, 
and in a letter to a colleague he described it as an artery or vein that lacks blood (4).   
The glandular function of the pancreas was first hypothesized by Reignier de Graaf.  While 
studying at Leiden in 1664, De Graaf investigated pancreatic secretion via the method of collecting 
pancreatic juices by cannulation of the pancreatic duct (6).  De Graaf was unable to identify the 
chemical composition of the collected pancreatic juice; he merely tasted it, and noted its ‘insipid’ 
and ‘acid-salt’ palate (3).  Although De Graaf was wrong in believing that pancreatic juice was 
acidic (pancreatic fluid has a pH around 8.6), he hypothesized that its primary function was for the 
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 segregation of food elements.  This hypothesis was later supported and espoused upon by 19th 
century German chemists Willy Kuhne and Alexander Marcet, who discovered the pancreatic 
digestive enzymes trypsin and lipase. However, the French physiologist Claude Bernard is credited 
with clarifying the function of the pancreas when he demonstrated the ability of pancreatic juice 
to emulsify fatty foods and convert starch into sugar (3). These discoveries and experimental 
investigations summarized above are just a few of the important contributions in determining the 
anatomy and physiology of the pancreas.   
 
 
1.2 Pancreas anatomy and physiology  
 The pancreas is a compound glandular organ, derived from the endoderm that is located in 
the retroperitoneum associated with several vital structures, which complicate diagnostic and 
therapeutic procedures.  Normally it has an average weight of 90 g, and is shaped like a tadpole, 
that is divided into four main anatomical areas: head, neck, body, and tail (7).  The pancreatic head 
is the thickest portion of the pancreas and lies within the C-loop of the duodenum, to the right of 
the superior mesenteric and portal veins.  The neck of the pancreas is the narrowest portion of the 
gland with a width less than 2 cm; lengthwise it traverses the mesenteric blood vessels anteriorly, 
connecting the pancreatic head and body. The pancreatic body is located between the neck and tail 
of the pancreas, and sits above the superior mesenteric artery and vein.  The pancreatic tail extends 
from the pancreas body to the splenic hilum.  The pancreatic duct (duct of Wirsüng) traverses the 
entire pancreas lengthwise and joins with the common bile duct, which drains secretions from 
acinar cells and bile into the duodenum via the duodenal papilla (papilla of Vater) (Figure 1.1A).  
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Figure 1.1: Anatomy and physiology of the pancreas.  (A)  Gross anatomy of the pancreas.  
(B) & (C) Exocrine and endocrine functional units of the pancreas.  The pancreas participates in
two major physiologic processes: digestion and glucose metabolism. (B) The endocrine portion 
of the pancreas, primarily responsible for regulating glucose homeostasis.  (C) The exocrine 
portion of the pancreas, responsible for secreting digestive enzymes (zymogens) into the ducts.  
Adapted from (314).   
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  As mentioned above, the pancreas functions as both exocrine and endocrine gland (a 
compound glandular organ) (Figure 1.1B & C). Approximately 85% of the pancreas is comprised 
of a branching network of acinar (meaning ‘cluster of grapes’) and duct cells.  These cellular 
clusters make up the exocrine portion of the pancreas that produce and deliver digestive pro-
enzymes, pancreatic fluid, and electrolytes into the gastrointestinal tract.  Acinar cells synthesize 
and secrete zymogen granules that are released at the cell apex by exocytosis into the ductal 
system.  Multiple defense mechanisms exist to prevent premature intra-acinar enzyme activation 
(a key feature of acute pancreatitis), by compartmentalization of zymogen granules from 
lysozymes, and by synthesizing trypsin inhibitors and antiproteases.  Normally, activation of the 
zymogens occurs in the duodenum, by cleavage of trypsinogen to trypsin via duodenal mucosal 
enteropeptidase, which in turn activates other digestive enzymes.      
  
 The endocrine pancreas constitutes approximately 2% of the pancreatic mass, and is 
identified by small ovoid clusters of cells called islets of Langerhans found dispersed throughout 
the pancreas, that are somewhat more plentiful in the pancreatic tail.  The islets are a highly 
perfused structure of cells in close proximity to fenestrated capillaries.  There are four main 
endocrine cells that compose the islets: i) α-cells that secrete glucagon, which promotes cells in 
the body to release glucose into the blood stream, ii) β-cells that secrete insulin, which promotes 
cells in the body to absorb glucose, iii) δ-cells that secrete somatostatin, which inhibits insulin and 
glucagon production and suppresses the release of gastric digestive enzymes, and iv) γ-cells that 
secrete pancreatic polypeptide, which regulates both exocrine and endocrine pancreatic secretion 
activities. The remaining 13% of pancreatic mass is composed of extracellular matrix, nerves, and 
blood vessels. 
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 1.3 Pancreatic cancer 
1.3.1 Epidemiology  
 Pancreatic cancer is the tenth most common malignancy, and is the fourth leading cause of 
cancer related mortality in both women and men in the western world.  It is predicted that by year 
2020, pancreatic cancer related mortality will surpass that of colon and liver cancer, making 
pancreatic cancer the second leading cause of cancer related death, placing it just behind lung 
cancer (8)(9).  The American Cancer Society estimates 48,960 new cases of pancreatic cancer for 
year 2015, and is estimated that 40,560 of these patients will succumb to the disease (8).  These 
numbers highlight the extremely dismal diagnosis of pancreatic cancer, which has a median 
survival of <6 months and a 5-year survival rate below 5%  (10). The majority of diagnosed 
pancreatic cancers are classified as pancreatic ductal adenocarcinoma (PDAC), which comprises 
roughly 85% of all diagnosed cases of pancreatic cancer, and is associated with a worse prognosis 
(11).       
 
 PDAC is associated with a variety of known demographic and environmental risk factors, 
which include smoking, advanced age, chronic pancreatitis, family history, obesity, and diabetes 
(12)(13)(14)(15)(16)(17).  The median age at which PDAC is diagnosed is 71 years, and it is rarely 
diagnosed in people younger than 40 years of age (11)(15).  At 80 years of age the risk factor for 
developing pancreatic cancer increases 40-fold (18). Computational models of PDAC that 
incorporate the number of somatic mutations, driver versus passenger events, and cellular 
proliferation as they acquire a cancerous phenotype, estimate that it takes an average of 11.7 years 
for initiating events that begin pancreatic carcinogenesis to develop into in situ cancer and a further 
6.8 years for primary tumor to develop metastatic clones (19)(20).  Once metastasis occurs patients 
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succumb to the disease, on average 2.7 years later (21); unfortunately, the majority of pancreatic 
cancer patients are diagnosed during the late-stage of disease making it difficult to provide 
therapeutic intervention.  However, if these computational models of PDAC development are 
correct, it provides a large time-window of opportunity for early detection and potential cure.  
Numerous studies have established the genetic basis for familial PDAC, and it is estimated 
that 5-10% of PDAC develops due to an inherited component (22)(23).  Corresponding germline 
mutations have been linked to familial PDAC, which include cyclin-dependent kinase inhibitor 2A 
(CDKN2A) (24), breast cancer 1 & 2 (BRCA1 & 2) (25)(26), liver kinase B1 (LKB1) (27), protease 
serine 1 (PRSS1) (28), and MutL homolog 1 (MLH1) (29)(30).  Mutations in cationic trypsinogen 
gene PRSS1 has one of the highest incidence rates associated with PDAC, and increases risk by 
53-fold (31).  PRSS1 mutations cause the cationic trypsinogen protein to be more effectively auto-
activated, consequently leading to pancreatitis (31).  Pathological processes such as pancreas 
exocrine organ dysfunction and inflammation are known to be an important risk factors in 
tumorigenesis, because they promote the release of growth factors, cytokines, and reactive oxygen 
species (ROS), and thus cause an increase in cell proliferation and accumulation of oncogenic 
mutations (30).         
1.3.2 Morphological characteristics of PDAC 
PDAC is a malignant epithelial neoplasm characterized by extensive desmoplasia.  Most 
commonly, the disease arises in the head of the pancreas and infiltrates into surrounding tissues, 
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 such as the lymphatics, peritoneum, and spleen (32).  The most common sites for distal metastasis 
are the liver and lung; however, PDAC metastasis has been reported in virtually all organs 
(33)(34)(35).  PDAC develops via a progressive model, and is defined by its histological and 
genetic pathology (Figure 1.2) (36)(19).  The precursor lesions that eventually develop into bona 
fide PDAC are termed pancreatic intraepithelial neoplasia (PanIN).  There are three classifications 
of PanIN characterized by increasing cytological atypia: PanIN-1, are composed of mucinous 
columnar epithelial cells with little cellular atypia; PanIN-2, are composed of papillary (rather than 
flat) epithelial cells and have some nuclear atypia; PanIN-3, have high-grade dysplasia and are 
referred to as carcinoma in situ (Figure 1.2) (19)(37). 
  
 The histopathology of PDAC resembles that of the ductal cells, and is where it derives its 
nomenclature.  Although this nomenclature implies that the neoplasm originates from ductal cells, 
its exact cellular origin (histogenesis) is still debated.  Studies in mice have allowed for the 
dissection of cellular lineages in their capability to develop into bona fide PDAC.  By targeting 
the activating mutation of K-RASG12D to the entire pancreas via the pancreatic and duodenal 
homeobox 1 (Pdx1) promoter, mice were capable of developing PDAC histologically similar to 
human disease (38).  This led to the speculation about the true cellular origin of PDAC.  
Premalignant acinar-to-ductal metaplasia is frequently observed in PDAC disease, and some 
hypothesize that this suggests a reprogramming of acinar cells to a duct-like phenotype as a 
possible mechanism for developing PDAC (39).  Supporting this hypothesis and highlighting 
acinar cells extensive plasticity, researchers used an acinar-specific promoter Elastase or muscle 
intestine and stomach expression 1 (Mist1) to activate oncogenic K-RASG12D, which resulted in 
the development of PanIN lesions and eventually PDAC (40)(41)(42);  in contrast genetic targeting  
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Figure 1.2: Morphological and genetic characteristics of PDAC progression.  Pictured are 
examples of the histopathology of PDAC development.  Normal ducts characterized by a single 
cell layer of low cuboidal epithelium (arrow) surrounded by periductal fibrotic tissue 
(arrowheads).  Pancreatic intraepithelial neoplasia (PanIN); increasing grade (1-3) reflects 
increasing atypia, eventually leading to PDAC.  PanIN-1 lesions present with elongation and 
mucinous hyperplasia of ductal cells (arrows), but lack cytological atypia. In contrast, PanIN-2 
lesions present with nuclear abnormalities, crowding (arrow), and papillary folding (bracket). 
PanIN-3 lesions present with severe nuclear atypia, loss of cellular polarity (arrows), and frequent 
mitosis.  PDAC is characterized by poorly formed neoplastic glands (asterisk), pronounced 
stroma, and invasive growth. The genetic alterations that accumulate in PDAC are thought to 
have temporal sequencing.  Mutations are classified by the following: early (telomere shortening 
and Kirsten rat sarcoma viral oncogene homolog (K-RAS)), intermediate (CDKN2A), and late 
(tumor protein P53 (TP53) and mothers against decapentaplegic homolog 4 (SMAD4)). Green 
arrows indicate activation and red arrows indicate loss of function mutations (see section 1.3.3 
genetic and molecular biology for more information).  Adapted from (19); hematoxylin and eosin 
(H&E) images re-printed with permission. 
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of ductal cells with a ductal-specific promoter Cytokeratin-19 to increase K-RAS expression, 
resulted in ductal cells that rarely gave rise to PDAC and were less susceptible to oncogenic K-
RAS initiated tumorigenesis when compared to acinar cells (43). It has also been proposed that 
centroacinar cells could be the cell of origin of PDAC (44), but like ductal cells, centroacinar cells 
do not readily form PDAC (45).  Others have hypothesized that pancreatic cancer stem cells, 
recently identified in PDAC (46), could be a possible candidate for PDAC cellular origin.  PDAC 
stem cells were shown to be highly tumorigenic, but it is yet to be shown whether these cells can 
develop disease from a mutated stem cell, or if they are the result of a cell regaining stem cell-like 
properties (46).   Thus, at least in mice, acinar cells exhibit a higher propensity to form PDAC in 
response to oncogenic mutation of K-RAS, whereas ductal and centroacinar cells are not as 
refractory to oncogenic transformation.  Finally, it is possible that there is no unique cell of origin 
in the human disease, and mutations that accrue in pancreatic cells give rise to PDAC with 
indistinguishable tumor phenotypes.   
1.3.3 Genetic and molecular biology 
One of the earliest and most pervasive molecular events that occur in premalignant ducts 
and all stages of PanIN is telomere shortening and dysfunction (47)(48).  Telomeres (TTAGGG 
sequences) become progressively shorter following cellular division.  Telomeres prevent fusion 
between chromosome ends, and their attrition leads to genomic instability and chromosomal 
rearrangements through breakage-fusion-bridge cycles that promote amplification, translocations, 
and deletions (49)(50).  Interestingly, it appears that telomere abnormalities occur more frequently 
in epithelial cancers and drive epithelial carcinogenesis (51).  Importantly, premalignant cells can 
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 avoid telomere shortening induced senescence by inactivating TP53-dependent DNA damage 
response (52), which cooperates with telomere dysfunction to promote the accumulation of 
oncogenic abnormalities (53).  Studies of telomerase-knockout mice support the model of TP53 
cooperating with telomere dysfunction (54) and in breast tumors telomere length shortening 
correlates with TP53 mutations (55).   
 
 Through molecular profiling of PanINs from pancreatectomy, researchers have reinforced 
the notion that PanIN-to-PDAC progression is highly associated with an accumulation of gene 
alterations, and that these genetic mutations associate with the histopathologic stages of PDAC 
(56).  Unlike some malignancies that can be driven by a single genetic mutation, such as leukemia, 
PDAC has been shown to have an average of 63 genetic alterations (57)(58).  Recent genome-
wide sequencing of PDAC provided insight into its molecular biology, and revealed a set of 14 
core signaling pathways and processes commonly altered in PDAC (56)(57)(59)(60) (Figure 1.3).  
Although these core pathways are commonly associated with PDAC, individual tumors vary vastly 
in terms of the pathways that are altered (57). Subsequent studies further highlight the vast 
heterogeneity of mutated genes in PDAC tumors, with 2,016 non-silent mutations and 1,628 copy-
number variations (58).  Despite this extreme heterogeneity among PDAC tumors, there are only 
a handful of genetic mutations that occur at a high frequency, suggesting that these mutations act 
as driver mutations for tumorigenesis.  These commonly observed mutations include the following: 
K-RAS, CDKN2A, TP53, and SMAD4.      
 
 The most common genetic mutation in PDAC is the activating point mutation at codon 12 
of the K-RAS gene.  K-RAS encodes a GTP-binding protein that mediates a wide variety of  
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Figure 1.3. PDAC core-signaling pathways and processes.  The fourteen signaling pathways 
and processes commonly associated with genetic alterations in the majority of PDAC.  These 
pathways were determined by whole exome sequencing of PDAC tumors, and provide a new 
paradigm in the development of next-generation pleiotropic treatments and therapeutic strategies.  
Figure adapted from (56)(57)(58)(59)(60).
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cellular processes, including induction of proliferation, survival, differentiation, and invasion (61).  
K-RAS mutations are one of the earliest genetic abnormalities to occur in pancreatic tissue,
detectable in about 30% PanIN-1 lesions, and increase in frequency with disease progression, with 
the frequency rising to nearly 100% in advance disease (62)(63)(64). Of note, K-RAS mutations 
are also found in patients with chronic pancreatitis a risk factor for PDAC suggesting that K-RAS 
mutations are driving forces in the development of PDAC (65).  Furthermore, genetically 
engineered mice with pancreatic specific K-RASG12D mutation develop PanIN lesions that progress 
to PDAC, albeit at a very slow rate (66)(67).  K-RAS activation engages a multitude of effector 
pathways, such as extracellular signal-regulated kinase (Ras-ERK), mitogen-activated protein 
kinases (MAPK), Ral guanine nucleotide dissociation stimulator (RalGDS) and 
phosphatidylinositol 3-kinase/protein kinase B (PI3K/Akt) pathway, thereby acting on a variety of 
downstream targets such as transcription factor nuclear factor kappa-light chain-enhancer of 
activated B cells (NF-κB) and mammalian target of rapamycin (mTOR) promoting cell survival, 
proliferation, angiogenesis, and invasion (68)(69).  
CDKN2A encodes for p16 protein, and regulates cell cycle progression from G1 phase to 
S phase.  CDKN2A also encodes for alternative reading frame protein (p14ARF), which inhibits 
mouse double minute 2 homolog (Mdm2), thus regulating cell cycle by promoting TP53 activity. 
Inactivating CDKN2A mutations occur in 80-95% of PDAC tumors and comprise the second most 
frequent genetic mutation detectable in moderately advanced PanIN lesions (70)(71). Loss of 
CDKN2A function is associated with promoter hypermethylation, mutation, and deletion (71).  
Germline mutations of CDKN2A alleles confer a 13-fold increased risk for PDAC (72)(73).  K-
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RAS mutations promote an increase in p16 expression, and thus it is hypothesized that CDKN2A 
inactivation may be  necessary to override cell senescence induced by K-RAS activation (74). 
TP53 tumor suppressor gene encodes for protein TP53, which regulates multiple anticancer 
functions, such as apoptosis, DNA repair, and cell cycle.  TP53 mutations are commonly 
associated with single-point mutations and observed in 75% of PDAC (75)(76).  TP53 mutations 
appear in late-stage PanINs that have acquired features of dysplasia, which highlights its function 
in preventing malignant progression (77)(78)(79).  Mice harboring pancreatic specific K-RASG12D 
activating mutation and deletion of TP53, have increased metastases compared to TP53 wild-type 
mice (80). It appears that TP53 may drive the prometastatic phenotype by inhibiting tumor 
protein/nuclear factor Y (TP73/NF-Y) complex, which represses platelet-derived growth factor 
receptor b (PDGFRb) and that blocking PDGFRb with small molecule inhibitors and ribonucleic 
acid (RNA) interference prevented PDAC metastasis (81). 
Another frequent PDAC associated mutation is the inactivation of SMAD4.  SMAD4 plays 
a central role in transforming growth factor beta (TGF-β) and bone morphogenic protein (BMP) 
signaling pathways (82)(83).  TGF-β signaling promotes fibroblast proliferation and epithelial-to-
mesenchymal transition (EMT) (83)(84)(85).  SMAD4 deletion/mutation occurs in 50% of PDAC 
cases, and is thought to occur in late stage PanIN or PDAC (86)(87).  Loss of SMAD4 expression 
is highly associated with metastasis, and in PDAC patients, loss of SMAD4 was observed in 22% 
of localized disease and 75% in patients with metastasis (88). It appears that loss of SMAD4 
promotes tumor spread predominantly via TGF-β signaling and that antibodies to TGF-β stem 
PDAC metastasis, while exogenous addition of TGF-β signaling cytokines enhanced invasion 
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(89)(90).  However, given the implication of BMPs in tumor metastasis in other malignancies, 
dysregulated BMP signaling may also contribute to PDAC spread, but currently is not as well 
studied in the PDAC setting (91)(92)(93)(94).  
The outcome of genetic studies described above have several mechanistic implications for  
PDAC pathobiology.  Although a core set of fourteen pathways is associated with PDAC, the 
pathway components that are altered in any individual tumor vary widely.  The described PDAC 
tumor heterogeneity among these pathway components can explain the difficulty in developing a 
therapeutic panacea or 'magic-bullet' cure.  A single therapeutic agent that is effective against a 
cancer cell containing the druggable target will give rise to subclones that lack the therapeutic 
target and thus are resistant.  This suggests that the best therapeutic strategies for PDAC may 
comprise in agents that target multiple core processes and signaling pathways, rather than a single 
altered genetic component.  Furthermore, the observation that PDAC develops sequentially by 
accruing mutations that promote PDAC progression and are associated with disease phenotype, 
may offer avenues for genomic and proteomic analysis that will aid in tumor typing and improve 
tumor classification, further improving patient specific therapy.    
1.3.4 Clinical presentation and diagnosis 
PDAC is a highly infiltrative malignancy with the majority of patients at the time of clinical 
diagnosis having lympho-vascular invasion and/or extensive metastasis.  Patients are typically 
asymptomatic until late in the course of the disease, thus making early diagnosis and therapeutic 
intervention difficult.  As mentioned earlier, the majority (60 – 70%) of PDAC tumors originate 
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in the head of the pancreas versus (20 – 30%) in the body and tail of the pancreas (95)(96).  The 
presenting symptoms and prognosis are related to PDAC location.  Patients with body or tail 
tumors tend to have decreased median survival compared to patients with tumors originating in 
the head of the pancreas (95)(96).  The differences are thought to be due to frequency of metastatic 
disease, and early onset of symptoms.  The most common presenting symptoms of PDAC are 
abdominal pain, weight loss, gastrointestinal symptoms, and asthenia (97).  Jaundice is commonly 
associated with tumors originating in the head, due to compression of the common bile duct.  Other 
physical symptoms of PDAC include palpable abdominal mass or gallbladder (98).    New-onset 
diabetes is present in roughly 50% of patients with PDAC, and should raise suspicion to the 
possibility of pancreatic cancer (99)(100).  An additional clinical finding is ‘thrombophlebitis’ or 
venous thromboembolism (VTE, Trousseau’s syndrome) (101). 
There is intense interest in identifying new pancreatic cancer biomarkers that go beyond 
screening and identifying disease.  These new tumor markers could have predictive and prognostic 
value, which will aid in stratifying patients based on disease aggressiveness, help select patient 
subsets for clinical trials, and help identify those who will respond favorably to therapy (Figure 
1.4).  Currently, the most common marker for pancreatic cancer is carbohydrate antigen 19-9 
(CA19-9). CA19-9 is currently the only Food and Drug Administration (FDA) approved biomarker 
for pancreatic cancer, and has a sensitivity of 70% and specificity of 87% (102)(103). Since 
pancreatic cancer has a relatively low prevalence among the general population, the ideal marker 
should have sensitivity and specificity that exceeds 99% to minimize false positives (104). Thus, 
CA19-9 is neither sensitive nor specific for screening and detecting pancreatic cancer, and it is 
typically used only for the follow-up of patients already diagnosed with the disease.  A decrease 
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 in postoperative levels of CA19-9 is the best index for improved patient prognosis, whereas in 
contrast, patients with increased CA19-9 after tumor resection have a significantly shorter median 
survival (105)(106).  Increased levels of CA19-9 may be due to nonmalignant diseases, such as 
chronic and acute pancreatitis, biliary obstruction cholangitis, and liver cirrhosis (102).  
Furthermore, patients who are Lewis antigen negative (Lea-b-) don’t synthesize CA19-9 because of 
a genetic absence of the Le enzyme (fucosyltransferase 3), and thus cannot test positive for CA19-
9 even during high tumor burden (107)(108)(109).  Therefore, between 5-10% of the general 
population will have undetectable disease when screened for CA19-9 (108)(109).      
  
 Imaging has become a crucial tool for determining initial diagnosis and staging, tumor 
resectability, and treatment monitoring.  Computed tomography (CT) is the single most important 
imaging tool for detecting and staging pancreatic cancer; however, other imaging technology, such 
as magnetic resonance imaging (MRI) and positron emission tomography (PET) have their 
advantages (110).  The accuracy of modern CT for detecting PDAC is fairly high, with some 
reports suggesting a sensitivity of 76-92% (110)(111)(112).  Primary PDAC tumors are typically 
not difficult to identify, due to their abundant fibrous stroma and hypovascularity.  However, 
smaller tumors can pose a challenge for visual identification and other signs of a mass must be 
used, such as pancreatic ductal dilation, biliary ductal dilation, abnormal pancreas contour, and 
pancreatic atrophy (110)(113). CT also has the ability to determine venous and arterial 
involvement, with new technologies having resolutions of <0.4 mm, allowing for the evaluation 
of major and minor mesenteric branch vessel tumor involvement (114).  Determining tumor 
vascular involvement is critical for identifying resect able and unresectable disease.  Whereas CT 
is the primary imaging technology used to identify PDAC lesions, MRI also has its utility.  MRI 
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Figure 1.4: Integration of diagnostic, predictive, and prognostic biomarkers for 
management of patients with pancreatic cancer.  There is an urgent need to develop predictive 
markers, markers that can identify subpopulations of patients who are likely to respond to a given 
therapy.  In contrast, prognostic markers provide information on the likely course of the PDAC 
disease.    Adapted from (109).  
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has greater soft-tissue contrast versus CT, and thus is useful in identifying small lesions 
(115)(116).  Unlike the anatomic imaging techniques CT and MRI, PET uses a radiotracer 18F-
fluorodeoxyglucose (FDG), which is a glucose analog that accumulates in cancer cells.  The 
sensitivity of PET is only 72%, and it is not recommended for screening; however, it does have 
value in differentiating between benign and malignant lesions, and may be superior to CT in 
evaluating therapeutic response (117).   
1.3.5 Treatment and management 
Currently, the only available curative treatment for PDAC is surgical resection.  In order 
to determine tumor resectability it is critical to assess primary tumor involvement with local 
vessels, such as superior mesenteric artery and vein, celiac artery, portal vein, and hepatic artery 
(118).   After determining tumor resectability the majority of patients do not qualify for surgery, 
only 10-20% of patients are considered to be candidates for surgical intervention, and many of 
these patients are found to have positive microscopic margins during surgery (119).  The anatomic 
location of the tumor determines the type of surgery performed.  Tumors located in the head and 
neck of the pancreas will undergo a pancreaticoduodenectomy (the Whipple procedure) (120).  
Tumors in the body or tail of the pancreas undergo left pancreatectomy, and it often includes a 
splenectomy (121).  Operative mortality at high-volume clinical centers is low and ranges from 1-
4% (122); however, post-operative morbidity is high with an average of 40% (123). Furthermore, 
the 5-year survival rate for patients who underwent tumor resection ranges from 15-25%, and it is 
estimated that 20% will develop local recurrence and more than 70% will develop metastatic 
disease (124).   
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Since the vast majority of PDAC patients do not qualify for tumor resection and have poor 
outcomes, chemotherapy remains the standard of care.  Gemcitabine has been the primary adjuvant 
and palliative cytotoxic therapy for PDAC since its approval in 1996 (125)(126).  However, 
gemcitabine alone has only a modest effect on overall survival (~6.7 months) (127), which 
suggests that drug monotherapy is inadequate to surmount the multitude of core-signaling 
pathways and processes associated with heterogeneous cancer cell populations.  Recently, two 
trials of combination chemotherapy regimens have emerged showing a survival advantage versus 
gemcitabine monotherapy (128)(129).  One trial incorporates the combination of fluorouracil, 
irinotecan, oxaliplatin, and leucovorin (FOLFIRINOX), and had a median survival rate of 11.1 
months, which was a 4.4 months improvement over gemcitabine monotherapy (128).  The second 
trial examined the combination of gemcitabine plus nanoparticle albumin-bound (nab)-paclitaxel, 
and had a median survival rate of 8.5 months versus the 6.7 months of gemcitabine alone (129).  
Both trials had a significant improvement in median survival, health status, and quality of life and 
currently are considered standard treatment for PDAC.   
As our knowledge of PDAC core-signaling pathways and processes expands, new 
opportunities to develop targeted therapies are increasing.  One such targeted therapy for 
pancreatic cancer is Erlotinib, a tyrosine kinase inhibitor of the catalytic domain of epidermal 
growth factor receptor (EGFR), which is over-expressed in 90% of pancreatic tumors (130).  
Erlotinib has been approved by the FDA for pancreatic cancer therapy, but following a Phase III 
study only showed marginal improvement when combined with gemcitabine versus gemcitabine 
only, with an overall survival benefit of roughly one month (131).  Currently, other compounds 
are being evaluated in Phase II/III clinical trials that target tumor stroma, immune response, and 
signal transduction pathways.  Pancreatic cancer is extremely stroma-rich, and this dense stromal 
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 compartment is thought to act as a physical barrier that prevents therapeutic agents from reaching 
cancer cells (132)(133)(134).  However, pharmacologic inhibitors that deplete tumor stroma had 
a worse overall survival, unrelated to drug toxicity (135).  It was later determined that the tumor 
stromal compartment plays an important role in restraining tumor growth and spread (136).  
Immunotherapy approaches that target immune checkpoint inhibitors are gaining track in solid 
tumors, especially in melanoma where they have received FDA approval (127).  However, 
therapies that target T-lymphocyte immunologic checkpoints in PDAC have been unfruitful, and 
studies of anti-cytotoxic T-lymphocyte-associated protein 4 (CTL4) and anti-programmed cell 
death protein 1 (PD-1) failed to demonstrate significant patient responses (137)(138).  These 
results may be due to the low number of tumor-infiltrating T-lymphocytes in PDAC, and currently 
investigators are exploring how PDAC avoids immune surveillance (139)(140)(141).  Researchers 
have also focused on targeting signal transduction pathways associated with PDAC.  One of the 
most pervasive and earliest effector signal transduction pathways associated with PDAC is K-
RAS, which is critical in promoting tumor initiation, progression, and tumor maintenance, thus 
making it a “holy grail” for PDAC therapy (142)(143)(144).  K-RAS has proven to be a 
challenging therapeutic target for multiple reasons: it has a high binding affinity to guanosine 
triphosphate (GTP), feedback loops, and a poor therapeutic window (144).  Recently, new 
compounds that can interact with the oncogenic mutant form K-RAS (cysteine-12 in G12C) have 
been identified, and are garnering hope for the identification of similar compounds that could 
interact with G12D and G13D K-RAS mutations (144)(145)(146).  In sum, targeted therapy in 
PDAC is for the most part still in experimental stages, and has yet to become a clinical standard.  
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 1.4 Tissue Factor  
1.4.1 Tissue Factor introduction  
 Tissue Factor (TF) (also named thromboplastin, Factor III, or CD142), derives its name 
from the ability of tissue extracts to initiate coagulation upon contact with blood or plasma.  In 
1905 Paul Morawitz, described the classical theory of blood coagulation.  This "classic" theory of 
blood coagulation describes four essential factors: thromboplastin, calcium, prothrombin, and 
fibrinogen (147).  Morawitz postulated that three of these components are always present in 
circulating blood, and the triggering factor thromboplastin must be released either from solid 
tissues or blood components.  Later in 1964, when additional coagulation factors were discovered 
two groups almost simultaneously described a new model of coagulation; the "waterfall" or 
"cascade" theory, which describes a sequential proteolytic activation of pro-enzymes that leads to 
the formation of thrombin (147)(147).  In 1981 Ronald Bach, Yale Nemerson, and William 
Konigsberg purified TF apoprotein (148), and subsequently its cDNA was isolated and sequenced 
(149)(150), thus establishing the field of TF research.     
 
 TF is a 47 kDa transmembrane glycoprotein that functions as the primary physiological 
initiator of blood coagulation by binding plasma FVII/FVIIa (151).  The TF:FVIIa complex 
promotes blood coagulation by activating both FX and FIX, which subsequently results in the 
generation of thrombin - forming a fibrin-rich hemostatic plug (151).   TF is encoded by the F3 
gene, located on chromosome 1 (p22-p21), which contains 6 exons.  These 6 exons of F3 produce 
a precursor protein with 295 amino acids, which undergoes post-translational modification – 
whereby the 32 amino acid signal peptide is removed.  The resultant mature protein consists of an 
extracellular domain (residues 1-219), transmembrane domain (residues 220-242), and a 
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 cytoplasmic tail (residues 243-263) and is referred to as full-length TF (152)(150)(153) (154) 
(Figure 1.5).  
 
 In 2003, Bogdanov et al. described an alternatively spliced isoform of TF termed 
alternatively spliced TF (asTF) (155).  asTF is the result of alternative splicing of the primary F3 
transcript, whereby exon 5 is omitted, resulting in the fusion of exon 4 and 6 creating a shift in the 
open reading frame and the generation of a unique 40 amino acid C-terminal domain (155)(156) 
(Figure 1.5).  This unique C-terminus lacks a transmembrane domain, and thus is secreted.  Since 
asTF retains the conserved Lysine (Lys) residues Lys165 and Lys166 (necessary for proteolytic 
activation of FVII and FX), some believe that asTF maintains FX activation, although at a 
diminished rate as compared to flTF due to the unique C-terminus causing a lower FVII affinity. 
However, its procoagulant function remains a matter of debate, some reports indicate asTF as 
being procoagulant and accruing in thrombi, but others exclude such a function, making its role in 
hemostasis  and/or thrombosis unclear (155)(157)(158)(159).  This discrepancy could be due to 
physiologically irrelevant conditions and the lack of validated and reliable assays for measuring 
asTF activity (160)(161).  Although the extent of its hemostatic function is controversial, multiple 
reports indicate that asTF possesses non-hemostatic functions, which have (patho)physiological 
implications in cancer (162).   
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Figure 1.5: Structure of TF protein variants. Full-length TF (flTF) is an integral 
transmembrane protein, whereas alternatively spliced TF (asTF) is a soluble protein.  Both 
isoforms contain the same first 166 residues, which share a N-terminal β-sandwich and the 
charged doublet Lys165:Lys166 (Purple circles).  There are 3 proposed Asparagine (Asn) 
glycosylation sites Asn11, Asn124, and Asn137 (“*” sign).  Yellow circle represent disulfide bridges 
at Cysteine (Cys) - Cys49-Cys57 and Cys186-Cys209.  Through alternative splicing of the primary 
transcript, a frame shift occurs and generates a unique C-terminus in the asTF protein (highlighted 
in pink).  asTF’s C-terminus contains a cluster of 5 positively charged residues (“+” sign), thought 
to facilitate asTF’s orientation on phospholipid surfaces.  The flTF C-terminus contains three 
serine residues (red circles), which undergo phosphorylation.    
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1.4.2 TF and cancer 
The molecular pathobiology of PDAC is marked by high expression of TF 
(163)(164)(165); which some hypothesize is the primary cause for elevated risk of thrombosis in 
patients with PDAC.  The association between thrombosis  and malignant disease has been 
recognized for well over a century (166).  In 1865, the French physician Armand Trousseau 
described the relationship between cancer and venous thromboembolism (VTE) (also known as 
Trousseau’s syndrome), and following Trousseau’s observation studies have provided a multitude 
of evidence for VTE risk in cancer (166)(167). Cancer is responsible for roughly 20% of all new 
cases of VTE, and the risk for VTE is elevated 7-fold in certain malignancies, and for some the 
risk is up to 28-fold (166)(167).   
TF is normally absent from quiescent endothelial cells, and is expressed in the adventitia 
and smooth muscle cells surrounding blood vessels.  Aberrant TF expression occurs in a variety 
of tumors, the result of oncogenic events.  In colorectal cancers mutations in TP53 and K-RAS, 
which activate MAPK and PI3K signaling pathways, induce TF expression (168)(169).  In human 
glioma cells, oncogenic EGFR and its mutant form EGFRvIII promote the expression of TF, 
protease-activated receptor (PAR-1), PAR-2, and ectopic synthesis of FVII, thus sensitizing the 
cells to TF/PAR-mediated signaling (170).  The loss of phosphatase and tensin homolog (PTEN) 
and tumor hypoxia in glioblastoma upregulates TF expression and increases the risk of 
intravascular thrombotic occlusion (171).  Also, other stimuli associated with malignant tissues 
such as TGF-β, tumor necrosis factor-alpha (TNF-α), interferon-gamma (IFN-γ), early growth 
response gene-1 (EGR-1), estrogen, Hypoxia-inducible factor 1-alpha (HIF-1α) are known to 
upregulate TF in cancer cells (172)(173)(174).    
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TF is highly expressed in PDAC as well as early PanIN lesions, and the expression of TF 
correlates with poor histologic grade and worse prognosis (175)(176). The function of TF is known 
to extend beyond hemostatic maintenance.  In nonsmall cell lung cancer (NSCLC) and PDAC TF 
expression significantly correlates with microvascular density (177)(178).  Both forms of TF play 
an important role in tumor growth and angiogenesis (162).  However, both flTF and asTF mediate 
tumor progression via unique mechanisms.  The flTF:FVIIa complex can enzymatically activate 
protein-coupled protease-activated receptors (PARS).  The flTF:FVIIa binary complex can 
activate PAR-2 and the flTF:FVIIa:FXa ternary complex can activate PAR1, which induce 
signaling cascades involving protein kinase C (PKC), PI3K, and MAPK family, p44/42, p38, and 
c-Jun N-terminal kinase (JNK).  These processes promote the production of pro-angiogenic
factors, such as vascular endothelial growth factor (VEGF) A and C, connective tissue growth 
factor (CTGF), as well as chemokines and cytokines chemokine (C-X-C motif) ligand 1 (CXCL1), 
interleukin-8 (IL-8), and granulocyte macrophage colony-stimulating factor (GM-CSF) 
(179)(162).  Blocking TF:FVIIa proteolytic function with a nematode anticoagulant protein 
(rNAPc2) diminishes vessel formation (180). Also of note, genetic deletion of flTF intracellular 
domain inhibits production of VEGF (181).  Not only does flTF mediate tumor progression via 
pro-angiogenetic mechanisms, but it also influences tumor metastasis by regulating actin 
dynamics.  In migratory cells, TF was shown to accumulate at the invasive edge, and actin-binding 
protein 280 (ABP-280) binds flTF’s intracellular domain (182).  flTF also regulates cell motility 
in a PAR-2 mediated mechanism, by upregulating Ras homolog gene family member A (RhoA) 
and cortactin proteins known to promote cell migration (183)(184).   
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In 2007, Hobbs et al. reported that asTF can facilitate angiogenesis, and showed that asTF 
overexpressing pancreatic cancer cells implanted into mice developed tumors associated with 
increased vessel density and size (185).  However, the mechanism underlying this finding wasn’t 
discovered until 2009 when van den Berg et al. reported that asTF mediates angiogenesis via non-
proteolytic ligation of β1 and β3 integrins (186).  Integrins are heterodimeric transmembrane 
receptors that function as adhesion molecules for cell-cell and cell-extracellular matrix (ECM) 
interactions, and can act as signal transduction platforms for a variety of biological processes 
(187).  Integrins are a diverse family of proteins composed of an α and β subunit: in humans there 
are 18 “α” and 8 “β” monomers that can combine with each other to form 24 unique integrins that 
bind to a wide variety of ECM molecules, such as fibronectin, fibrinogen, von Willebrand factor, 
collagen, and laminin, thus regulating cell adhesion to ECM (188).  Integrins also act as 
chemosensors to their microenvironment, nfluencing cell shape, survival, migration, and 
proliferation (188).  Non-proteolytic asTF-integrin mediated signaling mechanism is in striking 
contrast to flTF, whose tumor promoting mechanism relies on proteolytic PAR-dependent 
signaling.  Still, the role of asTF in tumor progression remains to be elucidated; with the knowledge 
that asTF interacts with integrins, we hypothesized that asTF enhances PDAC growth and spread 
as it accrues in the tumor stroma, acting as a non-proteolytic cell agonist.  
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Chapter 2: Alternatively spliced tissue factor 
contributes to tumor spread and activation of 
coagulation in pancreatic cancer  
I am lost: the phlebitis that has just appeared tonight leaves me no doubt about the 
nature of my illness. 
– Armand Trousseau
Malignancy, thrombosis and Trousseau: the case for an eponym 
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2.1 Abstract 
Alternatively spliced tissue factor (asTF) promotes neovascularization and monocyte 
recruitment via integrin ligation. While asTF mRNA has been detected in some pancreatic ductal 
adenocarcinoma (PDAC) cell lines and increased asTF expression can promote PDAC growth in 
a subcutaneous model, the expression of asTF protein in bona fide PDAC lesions and/or its role in 
metastatic spread are yet to be ascertained.  We here report that asTF protein is abundant in lesional 
and stromal compartments of the five studied types of carcinoma including PDAC.  Analysis of 
29 specimens of PDAC revealed detectable asTF in >90% of the lesions with a range of staining 
intensities.  asTF levels in PDAC lesions positively correlated with the degree of monocyte 
infiltration.  In an orthotopic model, asTF-overexpressing high-grade PDAC cell line 
Pt45P1/asTF+ produced metastases to distal lymph nodes, which stained positive for asTF.  PDAC 
cells stimulated with and/or overexpressing asTF exhibited upregulation of genes implicated in 
PDAC progression and metastatic spread.  Pt45P1/asTF+ cells displayed higher coagulant activity 
compared to Pt45P1 cells; the same effect was observed for cell-derived microparticles (MPs).  
Our findings demonstrate that asTF is expressed in PDAC and lymph node metastases and 
potentiates PDAC spread in vivo.  asTF elicits global changes in gene expression likely involved 
in tumor progression and metastatic dissemination, and it also enhances the procoagulant potential 
of PDAC cells and cell-derived MPs.  Thus, asTF may comprise a novel therapeutic target to treat 
PDAC and, possibly, its thrombotic complications. 
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2.2 Background 
Pancreatic cancer is the fourth leading cause of cancer associated death, and pancreatic 
ductal adenocarcinoma (PDAC) accounts for 85% of all forms of pancreatic cancer (189).  Several 
forms of solid malignancies are associated with a hypercoagulant state, which is thought to be 
partially caused by increased tissue factor (TF) expression on tumor cells due to, e.g., activation 
of proto-oncogenes such as K-RAS, EGFR as well as inactivation of tumor suppressor genes such 
as TP53 and PTEN (190).  TF-bearing microparticles (MPs) have also been thought to play a 
critical role in malignancy-associated venous thromboembolism (VTE).  Indeed, several studies 
indicate that cancer patients with VTE have significantly higher TF-MP activity and levels than 
cancer patients without VTE (191)(192), and such a link between TF-MP and VTE is confirmed 
by mechanistic studies (193).  Alternatively spliced TF (asTF) is a minimally coagulant isoform 
of full-length tissue factor (flTF) that drives angiogenesis nonproteolytically through binding to 
integrins α6β1 and αvβ3 (155)(186).  asTF-integrin interactions results in the activation of key 
signaling intermediates such as PI3K/Akt, p38 MAPK and FAK, resulting in endothelial 
neovascularization (186).  Moreover, asTF binding to β1 integrins on microvascular endothelial 
cells activates the NF-kB pathway that results in the increased expression of major cell adhesion 
molecules such as E-selectin, VCAM-1 and ICAM-1, leading to enhanced monocyte adhesion to, 
and migration through, endothelial cells (194).  Of note, α6β1 is expressed on PDAC cells, and the 
levels of this integrin are greatly potentiated by IL-1α; moreover, α6β1 induces Ras/ERK signaling 
resulting in the increased proliferation and migration of PDAC cells (195).  To date, studies of 
asTF in the cancer setting have been focused largely on cervical cancer (186)(194), and lung 
cancer: in 2008, asTF mRNA was found to be increased in squamous cell carcinoma of the lung, 
as well as pulmonary adenocarcinoma (196).  In tissues of non-small cell lung cancer, asTF mRNA 
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levels are highly predictive of patient outcome (197).  Studies of asTF in the PDAC setting have 
thus far been limited.  In 2006, screening of eight low- and high-grade PDAC-derived cell lines 
detected asTF mRNA expression in six cell lines (198).  In 2007, Hobbs et al. reported that 
overexpression of asTF in a TF-null PDAC line MiaPaCa-2 enhances tumor growth in a 
subcutaneous model; however, this study suffered from lack of mechanistic insight as well as 
conceptual limitations inasmuch as asTF was studied in a nonphysiologic, flTF-null setting (185).  
While the expression of flTF is well documented in human PDAC (Ref (178) and work cited 
therein), it is yet to be established whether asTF mRNA and/or protein are expressed in bona fide 
human pancreatic cancer tissue.  No data are available regarding the functional contribution(s) of 
asTF to PDAC pathobiology in physiologically relevant in vivo setting.   
In this study, we report for the first time that asTF (i) is expressed in human PDAC tumor 
tissue exhibiting heavy monocyte infiltration, (ii) promotes tumor metastasis in an orthotopic 
model of PDAC, (iii) exerts autocrine/paracrine effects on PDAC cells resulting in global changes 
in gene expression and (iv) contributes to the procoagulant potential of PDAC cells and cell-
derived MPs via distinct mechanisms.   
2.3 Materials and methods 
2.3.1 Reagents 
Human anti-asTF rabbit polyclonal antibody suitable for immunohistochemical studies 
was described and characterized previously (194)(200), Custom rabbit monoclonal antibodies 
RabMab1 (asTF-specific) and RabMab95 (recognizing a TF region shared by asTF and flTF) were 
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employed in Western blotting and ELISA assays.  For on-cell Western assays and flow cytometry 
analysis of intact cells and cell-derived MPs, flTF-specific mouse monoclonal antibody 10H10 
(194), and the rabbit monoclonal antibody RabMab1 were used.  Anti-GAPDH rabbit polyclonal 
antibody was from Trevigen, Inc. Isolectin B4 was from Invitrogen (Carlsbad, CA).  Anti-integrin 
β1/β3 and EGFR antibodies were from R&D Systems (Minneapolis, MN) and Biolegend (San 
Diego, CA), respectively.  TaqMan probe/-primer sets for EFEMP1, AREG and VEGF-A were 
from Roche Applied Science (Indianapolis, IN).  Anti-EFEMP1 polyclonal antibody was from 
Thermo Scientific (West Palm Beach, FL).  Anti-total MAPK/p-MAPK and total Akt/p-Akt 
antibodies were from Cell Signaling Technology (Beverly, MA).  Anti-CD68 antibody was from 
Imgenex (San Diego, CA).  Anti-F4/80 antibody was from Biolegend.  Mouse monoclonal anti-
human TF antibody 7G11 (200), was used as an inhibitory antibody in TF activity assays.   
2.3.2 Tumor tissue specimens 
Commercial tissue microarrays (TMA) were purchased from Imgenex Corporation (San 
Diego, CA).  Use of de-identified specimens of human PDAC tissue was approved by the 
Institutional Review Board, University of Cincinnati.  Twenty-nine specimens of primary PDAC 
tissue harvested from 26 patients were examined; in addition, five specimens of seminal lymph 
node metastases from four patients were available for and subjected to histological analysis.  The 
summary of clinicopathological characteristics of the PDAC cohort is provided in Figure 2.4, 
Supporting Information.  Immunohistochemical and fluorescence studies were performed as 
previously described (194);  asTF staining intensity was annotated by two trained anatomical 
pathologists based on the strength of the reaction obtained by HRP color substrate DAB.  PDAC 
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 specimens were stratified into the weak, moderate and strong subcohorts based on the staining 
intensity of ≥75% of tumor cells whose staining pattern was predominantly intracellular in nature; 
extracellular/stromal staining, when present, was also considered in scoring. 
 
 
2.3.3 Cell lines 
 Pt45P1 is a grade III human PDAC cell line that features key mutations characteristic of 
PDAC and has been previously shown to produce grade III tumors in nude mice (201).  Capan-1, 
a grade I human PDAC cell line, was obtained from ATCC (Manassas, VA).  Cells were cultured 
in IMDM (Capan-1) and DMEM (Pt45P1) supplemented with FBS in the presence of 
antibiotics/antimycotics and selective antibiotics, when appropriate.   
 
 
2.3.4 Overexpression of asTF in Pt45P1 cells  
 asTF open reading frame was subcloned in pSecTagA (Invitrogen, Carlsbad, CA) using 
restriction sites NheI and AgeI, and the integrity of the resultant expression construct was verified 
using automated sequencing.  The linearized construct was transfected into Pt45P1 cells using 
Fugene HD (Roche, Indianapolis, IN), and asTF-overexpressing clones were obtained using 
escalating concentrations of Zeocin as per the manufacturer's instructions, were pooled and 
expanded to establish asTF-overexpressing line Pt45P1/asTF+.   
 
2.3.5 Western blotting 
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Cells were grown to confluence in six-well plates, washed twice with PBS, lysed using 2X 
sample buffer containing 2-mercaptoethanol and denatured at 95°C for 5 min.  The lysates were 
loaded on 10% polyacrylamide gels and transferred to PVDF membrane.  The membrane was 
blocked for 1 hr using 5% nonfat milk and probed with the appropriate primary and the 
corresponding HRP-conjugated secondary antibodies (Invitrogen) using conventional techniques.  
The blots were developed using LumiLight (Roche), and chemiluminescent bands were visualized 
by exposure to X-ray film.  To verify equal loading, blots were then stripped and re-probed for 
GAPDH.   
2.3.6 Flow cytometry, ELISA and on-cell western assays 
Levels of various proteins and phosphatidylserine (PS) on the surface of nonpermeabilized 
cells and/or cell-derived MPs was measured using flow cytometry; in brief, PDAC cells and cell-
derived MPs were suspended in 50 μl of PBS or Annexin V staining buffer (Invitrogen), to which 
10 μg of the corresponding primary antibodies or 10 μL of Annexin V-FITC (Invitrogen) were 
added and incubated at RT for 30 min.  The cells were then washed twice with PBS, resuspended 
in 500 μL of PBS, incubated with the corresponding secondary antibodies (excluding Annexin V-
FITC samples) washed twice with PBS and analyzed; isotype IgG whole molecule preparations 
(Jackson Immunoresearch) served as negative/background controls.  All flow cytometry studies 
were performed using FACS Calibur (Becton Dickinson).  Levels of asTF in the conditioned 
medium were assessed using a sandwich ELISA; in brief, sample aliquots were placed in 96-well 
plates pre-coated with the capture antibody RabMab95 and incubated for 2 hrs; after subsequent 
washes, HRP-conjugated detection antibody RabMab1 was added for 1 hr, unbound antibody 
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washed away, o-Phenylenediamine was added and the plate was read at 405 nm in a colorimetric 
assay using a VersaMax microplate reader (Molecular Devices, Sunnyvale, CA).  For on-cell 
Western assays, intact cells (2 X 104 cells per well, Pt45P1 and Pt45P1/asTF+) were seeded in 96-
well plates, washed free of media with PBS and flash-fixed in 4% paraformaldehyde for 5 min at 
room temperature.  Cell surfaces were then blocked with 1X Power-Block (Biogenex, CA) and 
probed with the monoclonal flTF-specific antibody 10H10 and secondary anti-mouse IR-dye-800 
CW (LI-COR Biosciences, Lincoln, NE) to assess cell-surface flTF expression; imaging was 
carried using Odyssey IR scanner and quantified using Odyssey software (both from LI-COR).   
2.3.7 Microarray analysis 
Pt45P1 and Capan-1 cells were treated with recombinant human asTF preparations 
generated and characterized as previously described (186) for 4 hrs at a final concentration of 50 
nM; equal volumes of 50% glycerol in PBS served as the vehicle control.  Total RNA was isolated 
using RNAeasy Kit (Qiagen, Valencia, CA), reverse transcribed, amplified, fragmented and 
labeled for microarray analysis using the Nugen WTA Ovation FFPE kit and Encore biotin module 
(Nugen, San Carlos, CA) according to the manufacturer's instructions.  The labeled samples were 
hybridized onto Affymetrix Human Gene 1.0 ST chips.  Transcripts that were differentially 
expressed in Capan-1 and Pt45P1 cells - untreated and/or as a result of asTF treatment - were 
identified based on filtering for probe sets with Robust Multichip Average-normalized raw 
expression of at least 1.5-fold with p < 0.05 using a Welch t-test; the results of the analysis were 
uploaded to NCBI GEO (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE45928).  
Differences in gene expression between Pt45P1 and Pt45P1/asTF+ cells were assessed using 
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 RNAseq technology.  Samples from each cell line were analyzed in duplicate using Illumina 
TruSeq mRNA cDNA libraries that were sequenced using single-end 50 base reads at a depth if 
~20 million reads on an Illumina 2500 analyzer; the results were uplaed to NCBI 
(htpp://www.ncbi.nlm.nih.gov/sra?term=%28SRP020496%29).  Gene list enrichment analysis 
was performed using ToppGene (http://toppgene.cchmc.org/). 
 
 
2.3.8 Isolation of cell-derived MPs 
 5 X 105 Pt45P1 and Pt45P1/asTF+ cells were seeded in a T-75 flask and grown to 
confluence over 2 days.  The cells were then switched to serum-free defined media for 4 days, 
after which the conditioned media was collected and precentrifuged at 5,200g for 1 hr to remove 
cell debris.  The resultant MP-containing supernatant was ultra-centrifuged at 337,000g (NVTi 
65.2 rotor, Beckman) for 2.5 hrs.  The supernatant was carefully aspirated using a vacuum 
manifold and the remaining MP pellet was resuspended in PBS and used in flow cytometry 
analysis and/or Factor Xa generation assays.   
 
 
2.3.9 Two-step FXa generation assay  
 5 X 103 intact cells or 70 µL of cell-derived MP resuspended in HBS were incubated with 
FVIIa (Enzyme Research Laboratories, South Bend, IN) at the final concentration of 10 nM for 15 
min to pre-form a TF/VIIa complex.  Subsequently, FX (Enzyme Research Laboratories) was 
added to the samples at the final concentration of 100 nM and allowed to incubate for another 15 
min, after which CaCl2 was added to initiate FXa generation.  The reaction was stopped at 15 min 
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using EDTA-Bicine, and FXa substrate Pefachrome (Enzyme Research) was then added and OD 
405 nm recorded over a period of 1 hr using VersaMax microplate reader (Molecular Devices).  
All reactions were performed at 37°C. 
2.3.10 In vivo studies 
Use of laboratory animals and the experimental protocols were approved by the 
Institutional Animal Care and Utilization Committee, University of Cincinnati.  PDAC cells (1 X 
106 in 150 µL PBS) were orthotopically implanted in the pancreases of nude mice (age: 8 weeks; 
source: Harlan Laboratories, Indianapolis, IN; n = 3 per cohort, three independent experiments); 3 
weeks post-surgery, in vivo imaging was performed using in vivo multispectral imaging system 
FX (Kodak) employing a novel method to target tumors by Cell-Vue Maroon (CVM)-labeled, 
nanovesicle-coupled Saponin C protein fragment H2 (CVM-SapC[H2]-DOPS): such nanovesicles 
selectively target tumor cells as well as tumor vasculature enriched in externalized 
phosphatidylserine (202).  For quantification of tumor spread to distal lymph nodes, the images 
were analyzed in the corresponding anatomical locations or projections above and below the limbs 
in the lateral view using Carestream MI software, background fluorescence subtracted, data 
converted to photons per second per mm2, and the results averaged.  Following imaging studies, 
animals were sacrificed by intracardiac puncture, tissue specimens were harvested, fixed in 
formalin, embedded in paraffin and 4-µm sections analyzed using conventional techniques.   
2.3.11 Statistical analysis  
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Student’s t-test was used to assess the statistical significance of the differences between the 
groups; p < 0.05 was considered significant.  For multiple group comparisons, one-way ANOVA 
was used and Tukey post-hoc test was applied to derive p values.    
2.4 Results 
2.4.1 asTF protein levels in human PDAC tissue positively correlate 
with the density of stromal monocytic infiltrates 
To assess whether asTF protein is detectable in several forms of solid malignancies 
including PDAC, we performed IHC staining for asTF in commercial microarrays (TMA) 
comprising PDAC (n = 10), breast (n = 10), urothelial (n = 10), prostate (n = 9) and ovarian (n = 
10) carcinoma.  asTF immunoreactivity was observed in all examined tumor tissues, including
pancreatic intraepithelial (PanIN) - early-stage PDAC lesions - as well as advanced PDAC (Figure 
2.1A).  We also co-stained these tumor sections for CD68, a monocyte/macrophage marker, and 
observed strong asTF expression in tumor-infiltrating moncytes; nearly all tumor infiltrating 
monocytes expressed asTF, demonstrating that stroma cells, in addition to tumor cells, can also 
serve as a source of asTF in malignant tissue (Figure 2.1B).  Among the solid tumors studied, 
PDAC had the most monocyte infiltration, approximately twofold over the other four solid 
malignancies (p < 0.05, Figure 2.1C); of note, eight out of 10 PDAC specimens had some degree 
of detectable monocyte infiltration, whereas in the other four groups of specimens, monocyte 
infiltration was observed in ≤4 out of ten per group.  We then examined 29 specimens of resected 
PDAC tissue for asTF expression.  There was no appreciable staining for asTF in the normal 
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pancreatic tissue (areas adjacent to the tumor lesions, available in ~30% of all PDAC specimens 
examined) with the exception of islets of langerhans exhibiting consistently weak staining; asTF 
expression was detectable in over 90% of PDAC specimens (Figure 2.2 & 2.3A).  The tumor 
lesion as well as the associated stroma stained positive for asTF.  Occasionally, (peri)nuclear 
staining pattern was observed for asTF in some PDAC cells (Figure 2.3A).  In regional lymph 
node metastases, moderate levels of asTF expression were observed.  Based on the staining 
intensity of asTF in tumor lesions, we stratified the 20 PDAC specimens into three categories 
(weak = five specimens from five patients, moderate = 19 specimens from 17 patients and strong 
= five specimens from four patients); CD68 staining of the specimens revealed significantly higher 
levels of CD68+ infiltrating monocytes in the "stong-asTF" subcohort compared to the "weak" and 
"moderate" subcohorts (Figure 2.3B).  Isolectin B4 staining revealed paucity of vascularization in 
PDAC tissue specimens, which is consistent with the notion that PDAC is a hypovascular 
adenocarcinoma (203); still, one of the "strong-asTF' specimens exhibited a high degree of 
vascularization (Table 2.1A).  We note that 100% of "strong-asTF" patients presented with 
perineural invasion, compared to 60% in the "weak-asTF" subcohort and 65% in the entire PDAC 
cohort (Figure 2.4).   
2.4.2 asTF increases metastatic spread of high-grade PDAC cells in 
vivo  
A. charaacterization of asTF-overexpressing Pt45P1 cell line. To ascertain the role of
asTF in pancreatic tumor growth and metastasis, we used two well-characterized cell lines, namely 
Capan-1 and Pt45P1 cells which are grade I and grade III PDAC lines, respectively.  Semi-
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quantitative RT-PCR revealed that basal expression of asTF mRNA is higher in Pt45P1 cells 
compared to Capan-1 cells (Figure 2.5A); we then proceeded to overexpress asTF in Pt45P1 cells 
to establish the line we termed Pt45P1/asTF+, and verified asTF overexpression by RT-PCR and 
western blotting.  flTF expression appeared somewhat higher in Capan-1 compared to Pt45P1, and 
in Pt45P1 compared Pt45P1/asTF+ (Figure 2.5A).  flTF and asTF mRNA expression was then 
quantified using real-time PCR with reverse transcription, normalized to GAPDH (Figure 2.5B).  
Quantitative real-time PCR revealed no significant difference in flTF mRNA levels between 
Pt45P1 and Pt45P1/asTF+ cells, and Western blot analysis of total cell lysates revealed no 
difference in flTF protein levels among the three cell lines, yet asTF levels were higher in Pt45P1 
than in Capan-1 cells with Pt45P1/asTF+ displaying the highest levels of asTF protein (Figure 
2.5C).  Annexin V staining revealed no significant difference in the levels of externalized 
phosphatidylserine among the three lines (Figure 2.6A).   
B. asTF overexpression increases the aggressiveness of PDAC in an orthotopic model.
Nude mice were injected with 1 X 106 cells of Capan-1, Pt45P1 and Pt45P1/asTF+ (n = 3) 
orthotopically into pancreases, and tumor growth was monitored periodically using CVM-
SapC[H2]-DOPS-based in vivo imaging (Figure 2.6B).  After 3.5 weeks of orthotopic xenograft, 
we observed tumor growth in all three sets of mice; statistically significant evidence of enhanced 
distal metastases was observed in mice injected with Pt45P1/asTF+ cells compared to the Pt45P1 
cohort (Figure 2.6C).  The animals were then euthanized and upon necropsy, it became apparent 
that in Pt45P1/asTF+ mice, tumor cells spread to distal lymph nodes; of note, there were no 
differences between the cohorts in terms of tumor volume and/or mass at this early stage (not 
shown).  The excised tumors were then formalin-fixed, and paraffin sections stained for asTF 
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 which showed various degrees of asTF expression; the lymph node metastases from the 
Pt45P1/asTF+ mice were also immunoreactive for asTF (Figure 2.6B).  As we previously showed 
that asTF promotes angiogenesis (186), we tested the extent of neovascularization in the primary 
tumors and determined that Pt45P1/asTF+ tumors had the highest vessel density followed by 
Pt45P1 and Capan-1 tumors (p < 0.001) (Figure 2.7A).  F4/80 staining of tumor specimens 
revealed progressively higher monocyte infiltration of tumor stroma with the increasing levels of 
asTF produced by tumor cells (Figure 2.7B), which is in agreement with the results obtained using 
human PDAC specimens (Figure 2.3B). 
 
 
2.4.3 asTF induces global changes in gene expression in PDAC cells  
 Recently, it was reported that β1/β3 integrins - both engaged by asTF (155)(186) - 
synergize with EGFR to upregulate several kinases critical to cancer pathobiology (204)(205).  To 
explore whether short-term exposure to asTF protein can elicit autocrine/paracrine changes in 
PDAC cells, we treated Capan-1 and Pt45P1 cells with recombinant asTF (50 nM) or vehicle 
control for 4 hrs and assessed gene expression using microarrays.  Out of the 185 genes 
differentially expressed in Capan-1 and Pt45P1 cells, 19 were relevant to such processes as EGFR 
signaling, mesenchymal development and epithelial to mesenchymal transition (EMT) (Figure 
2.8A); western blotting revealed upregulation of MAPK and Akt phosphorylation in response to 
asTF (Figure 2.8B), and expression of EFEMP1 - the gene that promotes PDAC growth (206) - 
was upregulated in response to asTF in both PDAC cell lines (Figure 2.8C).  To explore the gene 
expression shifts elicited by sustained overexpression of asTF, we compared transcriptomes of 
Pt45P1 and Pt45P1/asTF+ cells using RNAseq; the results, summarized in (Figure 2.9), show that 
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asTF promotes upregulation of cell migration, MAPK signaling, EMT and wound healing 
processes while downregulating cell adhesion, phosphatase activity, inhibition of MAPK cascade 
and apoptosis; again, upregulation of MAPK activity in response to heightened asTF levels was 
observed, and increased phosphorylation of Akt was observed in Pt45P1/asTF+ cells compared to 
Pt45P1 cells when cultures were maintained in low serum (Figure 2.10A).  Interestingly, 
Pt45P1/asTF+ cells exhibited increased upregulation of EFEMP1 as well as AREG - recently 
shown to promote proliferation of PDAC cells (207) - and VEGFA (Figure 2.10B); 
immunohistochemical evaluation of tissue specimens confirmed upregulation of EFEMP1 protein 
expression in Pt45P1/asTF+ cells (Figure 2.10C).  Surface levels of β1/β3 integrins and EGFR 
did not differ in Pt45P1 and Pt45P1/asTF+ cells (Figure 2.13B). 
2.4.4 asTF contributes to the procoagulant potential of PDAC cell 
lines 
The procoagulant potential of asTF is still poorly defined and not universally recognized.  
asTF requires interaction with phospholipid surfaces to exert its weak procoagulant activity (155).  
We measured the TF-dependent procoagulant activity on PDAC cell surfaces using a standard 
endpoint two-step FXa generation assay.  We observed a significant increase in TF activity in 
Pt45P1/asTF+ compared to Pt45P1 (Figure 2.11A).  Cell-derived MPs isolated from conditioned 
media of Pt45P1/asTF+ cells also revealed a ~1.5-fold increase in TF activity compared to Pt45P1-
derived MPs (Figure 2.11B).  There was no difference in the total number of MPs generated by 
Pt45P1 and Pt45P1/asTF+ cells (Figure 2.13C).  To confirm the specificity of our assay, we 
performed control experiments using monoclonal antibody 7G11, which inhibits the activity by 
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hindering TF/VIIa interaction (200).  To address the possible contribution of altered flTF and/or 
asTF protein levels to the observed increase in procoagulant activity, we measured the surface 
level expression of flTF and asTF.  While there was a trend toward a decrease in surface flTF 
levels on Pt45P1/asTF+ cells compared to Pt45P1 cells, it did not reach significance neither by 
FACS nor by on-cell western assay; however, MPs generated by Pt45P1 cells (Figure 2.11C and 
Figure 2.13D).  Surprisingly, asTF was also detectable on the surface of Pt45P1 and Pt45P1/asTF+ 
cells and MPs; moreover, asTF surface expression was significantly increased in Pt45P1/asTF+ 
cells as well as MPs generated by them (Figure 2.11D); an approximately fivefold increase in the 
levels of free-secreted asTF protein was also seen in the MP-free conditioned media from the 
Pt45P1/asTF+ cells compared to Pt45P1 conditioned media (Figure 2.11D).  There was no 
difference in the levels of β1/β3 integrins on MPs generated  by Pt45P1 and Pt45P1/asTF cells 
(Figure 2.13E).  By ELISA, plasma of mice bearing Pt45P1 and/or Capan-1 tumors (Figure 
2.12A).  Exogenous addition of recombinant asTF resulted in a dose-dependent increase in TF 
procoagulant activity in Pt45P1 cells, whereas there was no such increase in TF activity when 
recombinant asTF was added to Pt45P1-derived MP preparations (Figure 2.12B). 
2.5 Discussion  
In this report, we show for the first time that asTF protein is expressed in human PDAC 
lesions; asTF is evidently produced by the tumor cells as well as the infiltrating monocytes.  
Pancreatic tumors tend to by hypovascular in nature, and pharmacokinetics-related issues are 
commonly associated with the treatment of PDAC (203).  While the human PDAC specimens in 
our study appeared largely hypovascular, a limitation of our study is that it involved a relatively 
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small number of PDAC specimens and, especially considering heterogeneity of PDAC tissue, 
better-powered studies involving (i) larger cohorts and (ii) in-depth examination of a larger tissue 
volume of each PDAC specimen are thus highly warranted.  Still, we invariably found heavy 
infiltration of monocytes in the tumor stroma; notably, the degree of monocyte infiltration 
positively correlated with asTF protein levels in PDAC lesions (Figure 2.3B).  The role of the 
flTF/asTF synergy in cancer pathobiology is very poorly understood.  Inflammatory stromal cells 
and infiltrating monocytes are crucial mediators of lymph-angiogenesis.  Lymphatic invasion of 
the tumor front and lymphatic metastasis is the major determining factor for PDAC metastasis 
(208).  We previously showed that asTF could act as an inflammatory mediator, inasmuch as its 
activation of endothelial cells yields enhanced monocyte adhesion and transmigration under 
chemokine gradients (186).  It is thus reasonable to propose that asTF expressed in the tumor cells 
and/or tumor-associated macrophages could play a role in PDAC metastasis.   
In all biological settings described to date, flTF and asTF are co-expressed; thus, we 
assessed the role of asTF in pancreatic tumors in an orthotopic model of PDAC using an flTF-
expressing PDAC cell line Pt45P1.  We find that asTF promotes tumor spread in this model, and 
it also drives angiogenesis as revealed by the increase in vascular density.  We observed an 
appreciable increase in macrophage infiltration in the orthotopically grown Pt45P1/asTF+ tumors, 
suggesting that our orthotopic model is suitable to study monocyte recruitment elicited by asTF in 
a PDAC setting (Figure 2.3B).  Hobbs et al. (185) have shown that asTF induces pancreatic tumor 
growth and angiogenesis in a sub-cutaneous model, but flTF paradoxically had an inhibitory effect 
on both, in contrast to findings of others who have convincingly determined that flTF expression 
is positively associated with tumor growth and angiogenesis (168)(162).  In this light, the 
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subcutaneous model employed by Hobbs et al. (185) has other serious limitations including, most 
significantly, a complete lack of recapitulation of the PDAC microenvironment and/or suitability 
in assessing metastatic potential.  Furthermore, the MiaPaCA-2 cell line that was used by Hobbs 
et al. (185) lacks the TF gene expression; since asTF is not found in the absence of flTF, this model 
is not suitable for assessment of the role of asTF and/or flTF/asTF synergy in tumor growth and 
metastasis.  We observed an increase in tumor vascularization in pancreatic tumors derived from 
asTF-overexpressing PDAC cell line, and it is reasonable to speculate that the underlying 
mechanisms of neovascularization are engaged by integrin-mediated signaling (186).  Our 
microarray data highlight the signaling changes elicited by asTF in PDAC cell lines.  asTF 
significantly activated various biological processes that are involved in tumorigenesis such as 
EGFR pathway and epithelial-mesenchymal signaling.  One of the genes activated by asTF is 
EFEMP1, whose product is a ligand for EGFR and competes with EGF for receptor binding; 
EFEMP1 has been shown to activate MAPK and Akt in inducing pancreatic tumor growth 
(206)(209).  Although PDAC tumors tend to be hypovascular, there is firm evidence that 
microvascular density in PDAC is comparable to that of other adenocarcinomas; moreover, VEGF 
expression levels are a significant and independent prognostic factor for advanced PDAC (210), 
and overexpression of asTF does increase VEGFA expression in PDAC cells (Figure 4.10B).  In 
this light, the increase in vascular density in our mouse model might be due to asTF-mediated 
induction of EFEMP1, which has been recently shown to activate VEGF and, subsequently, 
increase microvascular density in a PDAC model (206); Thus, we plan to assess the significance 
of the EFEMP1 expression for the asTF-PDAC axis with and without EGFR signaling inhibitors 
in future studies.   
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  Pancreatic cancer is associated with increased thrombosis, and VTE is a risk factor of 
mortality in most forms of cancers (211).  Haas et al. previously demonstrated that pancreas TF is 
substantially more immunoreactive in pancreatic cancer patients compared to those with chronic 
pancreatitis; importantly, plasma TF levels were heightened in patients with pancreatic cancer vs. 
controls and were particularly appreciable in patients that developed upper jugular and splenic vein 
thrombosis (198).  A recent study by Wang et al. revealed that the major source of TF activity 
affording systemic activation of coagulation in PDAC in the tumor itself, whereby clotting factors 
enter the tumor through neovessels and activate coagulation in a TF-dependent manner (212).  Our 
study shows that asTF may possibly synergize with flTF in promoting thrombosis in PDAC.  We 
show that asTF overexpressing PDAC cells are more procoagulant and that MPs derived from 
these cells also display enhanced cell surface membrane retention of asTF, but no significant 
change was observed in flTF levels.  The increased asTF retention on the cell membrane retention 
of asTF, but no significant change was observed in flTF levels.  The increased asTF retention on 
the cell membrane is perhaps due to its interaction with integrins which is not likely to affect asTF's 
ability to bind FVIIa.  Indeed, flTF in complex with β1 integrin on MPs appears to have full 
coagulant function, suggesting that the FVII binding site is preserved in integrin-bound TF (213).  
As asTF contains the FVIIa binding domain of flTF, it is possible that asTF binding to FVIIa leads 
to the overall augmentation of FX-to-FXa conversion in the presence of flTF on cell surfaces.  We 
note that asTF retention may also be accomplished through direct interaction with phospholipid 
bilayers (155).  As to the ability of asTF to increase flTF levels on PDAC cell-derived MPs, our 
findings closely echo those recently reported by Garnier et al., whereby promotion of EMT in 
colorectal cancer cells led to the release of extracellular vesicles carrying TF coagulant activity 
(214); addition of asTF to MPs derived from Pt45P1 cells did not augment total TF activity (Figure 
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2.12B), suggesting that the procoagulant potential of PDAC cell-derived MPs, while indirectly 
modulated by asTF, may very well be largely flTF-dependent.  Further studies are required to 
evaluate the kinetics and avidity of asTF/FVIIa interaction and the evidently EMT-mediated 
mechanisms underlying the enhanced presence of flTF on MPs derived from PDAC cells 
overexpressing asTF.  In sum, our results point to the role of asTF in the pathobiology of PDAC.  
The minimmaly coagulant asTF - a molecule that is not likely to significantly contribute to normal 
hemostasis yet may play a role in cancer-associated thrombosis as well as tumor spread - may 
serve as a novel target to treat PDAC and its thrombotic complications.   
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Figure 2.1: asTF expression and TAMs in human adenocarcinoma lesions. (original 
magnification: x40).  (A) asTF expression in TMA: specimen A – a diffuse staining pattern of 
asTF in PanIN; specimen B – cell surface expression of asTF; specimens C and D – asTF 
expression in highly aggressive PDAC. (B) CD68 staining of specimen D (original magnification: 
x10, primary antibody was used at 2.0 µg/mL); asTF expression is observed in the lesion, stroma 
and infiltrating monocytes. (C) Monocyte infiltration in various solid tumors; *p < 0.05. 
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Figure 2.2: asTF expression in human PDAC lesions.  (A) Representative images, top row: 
staining for asTF in non-malignant pancreas, i.e., duct cells, islets of Langerhans (indicated by 
arrows) and acinar tissue; middle row, staining for asTF in PDAC lesions (weak staining, ~15%; 
moderate staining, ~70%; strong staining, ~15% of all tissue specimens, n = 29); bottom row, 
PDAC metastases in regional lymph nodes.  Custom anti-asTF polyclonal antibody was used at 
2.0 µg/mL; original magnification: x40. 
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Figure 2.3: asTF expression patterns and TAMs in human PDAC lesions. (A) Expression 
patterns of asTF in PDAC.  Representative histological sections showing asTF staining patterns 
in PDAC displaying perineural invasion (images A and B), pancreatic intraepithelial neoplasia 
lesions (image C) and (peri)nuclear staining occasionally observed in PDAC cells, arrows (image 
D).  Intralesional variability of asTF protein expression was also observed in some PDAC 
specimens (image E). (B) CD68 staining in PDAC specimens exhibiting weak, moderate and 
strong staining for asTF (original magnification: x40, staining was carried out as in Fig. 2.1. 
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Characteristic All patient 
(n = 26) 
Weak asTF 
(n = 5) 
Strong asTF 
(n = 4) 
Median age, years (range) 65 (41 – 81) 62.5 (56 – 69) 57 (56 – 78) 
Sex: M/F 11/15 3/2 3/1 
pT category: T1/2/3 4/0/22 1/0/4 0/0/4 
pN category: N0/1/2 7/18/1 2/3/0 1/3/0 
Histological grade: G1/2/3 1/18/7 0/3/2 0/4/0 
Pathological margin: 
Involved/ uninvolved 
7/19 2/3 1/3 
Perilymphatic, perivascular 
Invasion: yes/ no 
4/21 1/4 1/3 
Perineural invasion: yes/ no 17/9 3/2 4/0 
Recurrence: yes/ no 11/15 3/2 1/3 
Median time to recurrence, 
Months (range) 
16 (10 – 22) 21 (16 – 22) 22 
 
 
 
 
 
  
Figure 2.4: clinicopathological characteristics, PDAC cohort. 
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Figure 2.5: Verification of flTF/asTF expression levels in Grade I (Capan-I) and Grade III 
(Pt45P1) PDAC cell lines.  (A, B) flTF/asTF expression by conventional and quantitative real-
time RT-PCR (n = 3).  (C) flTF/asTF protein levels in cell lysates (total protein, µg). 
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Figure 2.6:  asTF promotes PDAC spread in vivo. (A) Annexin-V staining (PS levels) by flow 
cytometry (n=3).  (B) PDAC cell lines were implanted orthotopically (three independent 
experiments, 3 mice per cohort), and 3.5 weeks post-surgery live animals were imaged using 
CVM-SapC(H2)-DOPS via tail injection.  The mice were then sacrificed, tumors were excised, 
formalin fixed/paraffin embedded, and stained for asTF (top row); side panel – isolated 
Pt45P1/asTF+ lymph node metastases. (C) Quantification of tumor spread to distal lymph nodes 
(CareStream software, Kodak).  
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Figure 2.7: Orthotopically implanted PDAC line Pt45P1/asTF+ exhibits the highest level of 
monocyte infiltration, and vessel density. (A) Vessel density as assessed by isolectin B4 
staining of the excised tumors. (B) Infiltration of tumor stroma assessed by anti-F4/80 staining; 
representative images are shown on top, 8 view fields per specimen (n = 3 per specimen type) 
were counted and averaged; primary antibody was used at 10.0 µg/mL.   
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 Figure 2.8: asTF protein elicits changes in gene expression in PDAC cells. (representative 
data, two independent experiments in duplicate).  (A) Heat map, Capan-1 and Pt45P1 cells were 
treated with recombinant asTF (50 nM) or vehicle control (PBS/glycerol) for 4 hours, total RNA 
was reverse transcribed, amplified, fragmented and labeled for microarray analysis; table: 
summary of the biological processes significantly altered in PDAC cells Capan-1 and Pt45P1.  
(B) Western blotting, phosphorylation status of MAPK and Akt in Pt45P1 cells treated with
recombinant asTF or vehicle control; (C) real-time quantitative RT-PCR, levels of EFEMP1 
transcripts in Capan-1 and Pt45P1 cells treated with recombinant asTF or vehicle control. 
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Figure 2.9: asTF protein elicits changes in gene expression in PDAC cells. (representative 
data, two independent experiments in duplicate).  Heat map, differences in gene expression 
between Pt45P1 and Pt45P1/asTF+ cells; table: summary of the biological processes significantly 
altered in Pt45P1/asTF+ cells. 
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Figure 2.10: Assessment of EMT-associated gene expression / kinase upregulation in PDAC 
cells overexpressing asTF. (A) Western blotting, phosphorylation status of MAPK and Akt in 
Pt45P1 cells and Pt45P1/asTF+ cells.  (B) Real-time quantitative RT-PCR, levels of EFEMP1, 
AREG, and VEGFA transcripts in Pt45P1 cells and Pt45P1/asTF+ cells. (C) 
Immunohistochemical analysis of EFEMP1 protein expression in Pt45P1 and Pt45P1/asTF+ 
cells. 
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Figure 2.11: Analysis of procoagulant activity in PDAC cell lines and determination of TF 
isoform levels on nonpermeabilized cells and cell-derived MPs.  (n ≥ 3 experiments per each 
sample type).  (A)  TF activity on cell surfaces.  (B)  TF activity on cell-derived MP.  (C) Cell-
surface and MP expression of flTF protein.  (D)  Cell surface and MP expression of asTF protein; 
levels of asTF secreted in the culture media.  
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Figure 2.12: Circulating levels of  arterial asTF and analysis of procoagulant activity of 
PDAC cells and MPs.  (n ≥ 3 experiments per each sample type).  (A) Levels of asTF protein in 
the plasma of mice bearing tumors as indicated (six plasma samples per type, collected during 
two independent in vivo studies).  (B)  Effect of recombinant asTF on TF procoagulant activity 
on the surfaces of intact cells and cell-derived MP.  *p < 0.05, i.t. – in-trend, 0.1 < p < 0.05. 
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Figure 2.13: supplementary material.  (A) Quantification of vessel density in the PDAC 
specimens stratified into weak asTF and strong asTF cohorts.  (B) Levels of β1/β3 integrins and 
EGFR on the surface of Pt45P1/asTF+ cells (n ≥ 3). (C) Total number of microparticles generated 
by Pt45P1 and Pt45P1/asTF+ cells (n ≥ 3).  (D)  Levels of flTF protein on cell surfaces assessed 
using on-cell western assay (n = 3).  (E)  Levels of β1/β3 integrins on the surface of MP generated 
by Pt45P1 and Pt45P1/asTF+ cells (n = 3).   
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Chapter 3: Levels of alternatively spliced 
tissue factor in the plasma of patients with 
pancreatic cancer may help predict 
aggressive tumor phenotype  
 
 
In the field of observation, chance favors the prepared mind. 
 
– Louis Pasteur 
 Lecture, University of Lille, December 7, 1854 
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 3.1 Abstract 
 Background.  Circulating ('blood-borne') tissue factor (TF) is implicated in the 
pathogenesis of several chronic conditions, most notably cardiovascular disease, diabetes, and 
cancer.  Full-length TF is an integral membrane protein, while alternatively spliced TF (asTF) can 
be secreted and, owing to its unique C-terminus, selectively detected in biospecimens.  The 
predictive and/or prognostic value of asTF in the circulation is unknown.  In a retrospective study, 
we measured levels of circulating asTF in healthy subjects and individuals with acute coronary 
syndrome (ACS), diabetes mellitus (DM), ongoing ACS + DM, and pancreatic ductal 
adenocarcinoma (PDAC).  Methods. The prototype-tailored procedure (Diagnostica Stago) was 
used to measure asTF in plasma from 205 subjects.  Results.  There was no significant difference 
between the proportion of healthy subjects with asTF ≥200 pg/mL and those with ACS, DM, or 
ACS + DM.  The proportion of pancreatic cancer patients (n = 43; PDAC: 42; pancreatic 
neuroendocrine tumor: 1) with asTF levels ≥200 pg/mL was significantly higher than in healthy 
subjects; asTF levels ≥200 pg/mL were detected more often in patients with unresectable disease 
irrespective of initial evaluation and/or preoperative carbohydrate antigen 19-9 (CA19-9) levels.  
Conclusions.  While asTF levels ≥200 pg/mL are not observed with increased frequency in patients 
with ACS and/or DM, they do occur more frequently in the plasma of patients with pancreatic 
cancer and are associated with lower likelihood of tumor resectability, irrespective of the 
preoperative diagnosis.  asTF may thus have utility as a novel marker of aggressive pancreatic 
tumor phenotype. 
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 3.2 Background     
 Tissue Factor (TF) is a glycoprotein that serves as the primary initiator of blood 
coagulation.  In the late 1990s, Key et al. and Giesen et al. demonstrated the presence of 
procoagulant TF in the blood of healthy individuals, which was contrary to the notion that TF only 
resided in the adventitia acting as a hemostatic envelope (215)(216).  This paradigm shift was later 
confirmed by other groups demonstrating that blood monocytes in healthy individuals express low 
levels of TF (217).  TF in cell-free plasma ('blood-borne' or circulating TF) occurs in two forms: 
full-length TF (flTF) which contains a transmembrane domain, and alternatively spliced TF (asTF) 
which lacks a transmembrane domain and can thus be secreted (155)(218).  Circulating flTF is 
associated with blood cells and microparticles, whereas the unique C-terminal domain of asTF 
enables it to be released in a free form and circulate in the blood of humans and mice.  asTF is 
detectable in a variety of healthy and diseased tissues, including spontaneously formed thrombi, 
atherosclerotic plaques, and cancer lesions (155)(219)(220).   
  
 Total circulating TF is elevated in diabetes mellitus (DM) (221), acute myocardial 
infarction (222), and pancreatic cancer (223).  These diseases not only have elevated levels of TF 
antigen in the blood but also heightened levels of circulating TF activity, which increases the risk 
of thrombosis (221)(222)(223).  TF is elevated in patients with acute coronary syndrome (ACS), 
and may be predictive of fatal and nonfatal cardiovascular events in patients with ACS (222)(224).  
DM plasma was reported to have heightened TF procoagulant activity (225); we note that 
approximately 80% of patients with DM will die from various forms of thrombosis (226).  In 
contrast to circulating procoagulant flTF, which is elevated in benign disease 
(221)(222)(223)(224)(225)(226)(227), it is not known whether the same is true regarding 
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 circulating asTF.  Recently, asTF was shown to be present in the blood of metastatic breast cancer 
patients at concentrations exceeding 1 ng/mL (228), and overexpression of asTF by cancer cells 
promoted primary tumor growth and metastatic spread in an orthotopic model of pancreatic ductal 
adenocarcinoma (PDAC), the most common form of pancreatic cancer (>70%) (229).  asTF acts 
as a cell agonist driving angiogenesis, cancer cell proliferation, and monocyte recruitment via 
integrin binding (186)(194)(224)(228)(229).   
  
 Non-proteolytic biological activity of asTF notwithstanding, there is currently no 
consensus as to whether asTF is able to contribute to normal hemostasis and/or thrombogenesis, 
or whether circulating asTF may serve as a biomarker in patients suffering from cardiovascular 
disease, diabetes, and/or cancer, including PDAC.  The majority of patients with PDAC are 
unresectable; among the minority of patients initially deemed resectable, vascular invasion, 
metastatic spread to the peritoneal cavity, liver, lymph nodes and/or other distal sites are common 
and a substantial subset of patients with PDAC initially considered resectable will be deemed 
unresectable following exploratory laparotomy.  Carbohydrate antigen 19-9 (CA19-9) is the only 
approved biomarker that appears somewhat helpful as a circulating preoperative indicator of 
unresectable PDAC (230); however, it has serious limitations in that Lewis-a-negative individuals 
do not express CA19-9, and it is thus absent in approximately 10%  of the general population.  
Another limitation of CA19-9 is that it is elevated in several benign conditions, including liver 
cirrhosis, viral hepatitis, pancreatitis, and cholelithiasis.   
  
 Currently available assays for measuring circulating 'total TF' antigen and activity have 
varying sensitivity and specificity (231), and may or may not cross-react with asTF.  Recently, we 
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 reported that a newly developed asTF-specific sandwich enzyme-linked immunosorbent assay 
(ELISA) prototype can detect asTF in the plasma of mice bearing human PDAC tumors (232).  
Using this innovative ELISA, we have now measured asTF in the plasma of healthy subjects and 
patients with ongoing ACS, DM, ACS + DM, and PDAC to evaluate the potential of asTF as a 
PDAC-specific circulating biomarker.   
 
 
3.3 Methods   
3.3.1 Study subjects and sample collection 
 The study set comprised the following: platelet poor plasma (PPP) from subjects enrolled 
in the previously described Disposition Impacted by Serial Point of Care Markers in Acute 
Coronary Syndromes (DISPO-ACS) study (233); PPP from patients who donated their 
biospecimens to the University of Cincinnati Cancer Institute's Tumor Bank (UCCI-TB);  PPP 
from patients with end-stage PDAC (Diagnostica Stago collection); and a cohort of age/sex-
matched healthy individuals custom-ordered from Innovative Research, Inc.  All plasma 
specimens were collected as per the approved protocols in their respective institutions.  Power 
calculations were based on (223) to arrive at the minimum required number of subjects per each 
subcohort. 
  
 The DISPO-ACS group comprised 142 subjects.  Specimens were selected to include (i) 
persons presenting to an emergency room with chest pain but who had no disease diagnosed and 
a negative troponin test, no history of coronary artery disease, and no history of DM (n = 38); (ii) 
ACS as determined by positive troponin levels (n = 39); (iii) self-identified DM (n = 40); and (iv) 
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 combined ACS + DM (n = 25); subjects with cancer were excluded.  Venous blood was drawn 
into tubes containing heparin; the presence of heparin does not affect the sensitivity of asTF ELISA 
(data not shown).  Blood samples were centrifuged at 3,000 rpm for 15 min at 4°C; PPP was 
collected and stored at -80°C until use.   
  
 The pancreatic cancer group comprised 39 PPP samples from patients (PDAC: n = 38; 
pancreatic neuroendocrine tumor [pNET]: n = 1) who underwent treatment at the University of 
Cincinnati (UCCI-TB cohort), and four cases of end-stage PDAC from the Diagnostica Stago 
collection.  In the UCCI-TB cohort, 25 patients, including the single case of pNET, were confirmed 
resectable/underwent surgery, and 14 patients were deemed unresectable due to locoregional 
spread identified during laparoscopic examination.  The four PPP samples from the Diagnostic 
Stago collection were from patients suffering from end-stage PDAC/metastases to distal sites.  
Resectability was defined as no involvement of superior mesenteric artery, less than 180° 
involvement of superior mesenteric vein, no involvement of hepatic artery, no involvement of 
celiac artery, and no locoregional metastases.  None of the patients were jaundiced prior to surgery; 
average tumor volume was 12.01 ± 12.10 cm3 (smallest specimen: 1.21 cm3; largest specimen: 
56.88 cm3).  Among the 25 patients who underwent tumor resection, lymphatic/vascular 
involvement was identified in 11 patients; six received neoadjuvant chemotherapy (two 
gemcitabine, three gemcitabine/ abraxane, one gemcitabine/ cisplatin), and four underwent 
chemoradiaotherapy prior to surgery.  PPP samples from healthy controls were provided by 
Innovative Research, Inc., and comprised 20 age/sex-matched prescreened subjects.  Venous blood 
was collected in acid citrate dextrose tubes and processed as above.   
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 3.3.2 Enzyme-linked immunosorbent assay (ELISA) and statistical 
analysis       
 PPP samples were assayed for asTF using a custom sandwich ELISA as previously 
described (232).  In brief, 96-well plates were coated with an anti-asTF rabbit monoclonal capture 
antibody and probed with an asTF-specific peroxidase-conjugated detection antibody.  In healthy 
individuals, circulating asTF levels were reported to be ≤100 pg/mL (234).  The asTF ELISA 
sensitivity cutoff was 50 pg/mL; for the purposes of intracohort statistical analyses of prevalence, 
the threshold was set at 200 pg/mL - near the lowest concentration range at which asTF begins to 
exert its integrin mediated (patho)biological activity (194).   
  
 PPP samples from the UCCI-TB cohort were also assayed for CA19-9 using a commercial 
ELISA (Calbiotech, catalogue number CA199T).  A CA19-9 level of 130 U/mL was treated as the 
optimal cutoff value useful in non-invasive determination of PDAC resectability (230).  Kruskkal-
Wallis one-way analysis of variance was used to test for differences; Chi square or Fisher's exact 
test was used to compare the proportion of PPP samples with the levels of asTF ≥200 pg/mL.  
Statistical analyses were performed using GraphPad and SigmaPlot 13.0 software packages and p 
values <0.05 were deemed significant. 
 
 
3.4 Results  
 Levels of asTF ≥200 pg/mL were detected in the plasma of 7/38 (18 %) subjects in the 
DISPO-ACS control cohort, 5/39 (13 %) in the ACS cohort, 2/40 (5 %) in the DM cohort, and 
4/25 (16 %) in the ACS + DM cohort.  asTF concentrations were non-normally distributed, and 
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 there was no significant difference in the mean asTF concentrations (p = 0.310) and/or the 
proportion of subjects with plasma asTF levels ≥200 pg/mL between the four DISPO-ACS cohorts 
(p = 0.272; Figure 3.1).  The demographics and prior medical history of DISPO-ACS subjects 
whose asTF levels were ≥200 pg/mL, and those with asTF levels <200 pg/mL, did not differ 
significantly (Figure 3.2). 
  
 In the UCCI-TB pancreatic cancer cohort there was a significantly higher proportion of 
subjects with levels of asTF ≥200 pg/mL compared with age/sex-matched healthy subjects, i.e. 
16/39 (41 %) patients with pancreatic cancer versus 3/20 (15 %) healthy subjects (p = 0.037) 
(Figure 3.3).  As in the DISPO-ACS cohorts, asTF concentrations were non-normally distributed; 
following exploratory laparoscopy, 11 of 36 UCCI-TB patients initially deemed resectable were 
deemed unresectable due to locoregional spread.  When the UCCI-TB cohort was split into bona 
fide resectable (n = 25) and unresectable (n = 14) subcohorts, asTF levels ≥200 pg/mL were 
significantly more prevalent in the unresectable subcohort irrespective of the results of initial 
evaluation; unresectable disease was identified in 9 of the 16 patients with asTF ≥200 pg/mL, and 
in 5 of the 23 patients with asTF levels <200 pg/mL (56 % vs. 22 %; p = 0.006).  Diabetes, vein 
resection, and/or nodal metastases were not significantly more prevalent in the unresectable 
subcohort (Figure 3.4). 
  
 Absolute levels of asTF were measured in the PPP of matched healthy subjects (n = 20): 
resectable (n = 25) and unresectable (n = 14) patients comprising the UCCI-TB cohort, and also 
patients with end-stage disease (Diagnostica Stago collections, n = 4).  As shown in Figure 3.5, a 
trend toward the increase in absolute asTF levels was discernible (resectable vs. unresectable 
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 patients), which reached strong statistical significance when the resectable subcohort was 
compared with the end-stage disease subcohort. 
  
 CA19-9 levels ≥130 U/mL were detected in 12 of the 39 (31 %) PPP samples from the 
UCCI-TB cohort, of which 7 (58 %) had unresectable disease (Figure 3.6).  There was no 
significant correlation between CA19-9 levels and asTF levels (Figure 3.7).   
 
 
3.5 Discussion      
 In our study, circulating asTF levels ≥200 pg/mL was not significantly associated with 
ACS and/or DM.  The lack of a difference between subjects without ACS and those with ACS 
and/or ACS + DM likely indicates that asTF is not elevated in the circulation during the acute 
phase of ACS, yet it remains to be definitively ascertained whether asTF is elevated in the 
circulation of patients with cardiovascular disease; we note that asTF is found in abundance in 
lipid-rich atherosclerotic plaques and may increase their destabilization as it is proangiogenic and 
promotes monocyte recruitment (194).   
  
 Circulating asTF levels ≥200 pg/mL were significantly more frequent in patients with 
pancreatic cancer compared with age- and sex-matched healthy subjects and all other subject 
groups examined (41 % vs. 5-18 %, respectively), and patients with plasma asTF levels ≥200 
pg/mL were significantly less likely to qualify for tumor resection.  The current standard in staging 
PDAC is anatomic imaging, but its accuracy in determining resectability is only 75 %, resulting in 
approximately 25 % of patients undergoing unnecessary laparotomy (235).  Moreover, the 5-year 
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 survival rate following tumor resection is less than 20 % (236) and new biomarkers that help detect 
more aggressive PDAC phenotypes are thus much needed.  Currently, the only approved FDA 
biomarker is CA19-9, a sialylated Lewis-a antigen produced by exocrine epithelial cells of the 
digestive tract.  CA19-9 may act as a ligand for E-slectin but its precise biological role and 
contribution to PDAC pathogenesis are not clear.  Lewis-a-null individuals do not express CA19-
9, and it is thus unusable as a biomarker in approximately 10 % of the population; another 
limitation is that CA19-9 can be elevated in benign disease (237)(238).  While CA19-9 may be a 
suboptimal general screening tool in PDAC, preoperative CA19-9 levels have shown some 
promise in determining resectability in PDAC patients; a study designed to determine the optimal 
preoperative CA19-9 cutoff level associated with tumor unresectability reported that such value is 
130 U/mL.  Of the 262 pancreatic cancer patients enrolled in that study, 55 % had CA19-9 levels 
≥130 U/mL, and 26 % of these were determined to be unresectable (230).  Plasma asTF levels 
≥200 pg/mL were present in 41 % of the pancreatic cancer patients in the UCCI-TB cohort, and 
56%  had unresectable disease, indicating that plasma asTF levels ≥200 pg/mL are likely non-
inferior to CA19-9 in predicting  unresectability.  Interestingly, there was no correlation between 
plasma asTF and CA19-9 and, among the 14 UCCI-TB PDAC patients with unresectable disease, 
five had asTF ≥200 pg/mL, threee had CA19-9 ≥130 U/mL, and only four had both.  We note that 
none of the resectable patients had asTF ≥200 pg/mL and CA19-9 ≥130 U/mL.   
  
 A significant limitation of our study is that the numbers of subjects in all cohorts we 
examined were small, rendering it difficult to draw definitive conclusions at this time.  However, 
our observations regarding plasma asTF levels in pancreatic cancer patients vis-à-vis their 
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 eligibility for tumor resection are qualitatively novel and will thus serve as an impetus for our 
group and, hopefully, other investigators to explore asTF's utility in larger cohorts. 
 
 
3.6 Conclusions      
 Measuring asTF in plasma may help identify pancreatic cancer patients with more 
aggressive disease, yet low CA19-9 levels in circulation.  Plasma asTF, a protein that, unlike 
CA19-9, is known to promote PDAC progression (229), may thus comprise a novel biomarker of 
aggressive disease with a potential utility in non-invasive determination of tumor resectability yet 
evidently no drawback of being elevated in benign conditions traditionally ascribed to plasma TF.  
A prospective study to determine whether plasma asTF may also be useful in longer-term patient 
stratification is currently underway. 
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Figure 3.1: Plasma asTF levels, DISPO-ACS study.  Dot-plot, circulating asTF (pg/mL).  Thick 
bars indicated mean asTF concentrations; thin bars indicate SD. SD standard deviation, CAD 
coronary artery disease, MI myocardial infarction, asTF alternatively spliced tissue factor, 
DISPO-ACS Disposition Impacted by Serial Point of Care Markers in Acute Coronary Syndrome, 
ACS acute coronary syndrome, DM diabetes mellitus.  
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Figure 3.2:  Subject demographics, DISPO-ACS study.  Demographics and characteristics of 
the subjects comprising the DISPO-ACS subcohorts.  SD standard deviation, CAD coronary 
artery disease, MI myocardial infarction, asTF alternatively spliced tissue factor, DISPO-ACS 
Disposition Impacted by Serial Point of Care Markers in Acute Coronary Syndrome, ACS acute 
coronary syndrome, DM diabetes mellitus.  
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Figure 3.3: Plasma asTF levels, UCCI-TB pancreatic cancer cohort and age/sex-matched 
healthy subjects. Dot-plot, circulating asTF (pg/mL).  Thick bars indicate mean asTF 
concentrations; thin bars indicate SD.  SD standard deviation, asTF alternatively spliced tissue 
factor, UCCI-TB University of Cincinnati Cancer Institute’s Tumor Bank. 
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Figure 3.4: Subject demographics, UCCI-TB pancreatic cancer cohort and age/sex-
matched healthy subjects. Demographics and characteristics of the subjects comprising the 
UCCI-TB cohort.  SD standard deviation, asTF alternatively spliced tissue factor, UCCI-TB 
University of Cincinnati Cancer Institute’s Tumor Bank. 
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Figure 3.5:  Absolute levels of asTF in PPP of age/sex-matched healthy subjects, patients 
who underwent tumor resection, patients deemed unresectable and patients with end-stage 
disease.  Thick bars indicate mean asTF concentrations; thin bars indicated SD.  asTF 
alternatively spliced tissue factor, SD standard deviation, PPP platelet-poor plasma, n.s. not 
significant.   
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Figure 3.6: Plasma CA19-9 levels and subject demographics, UCCI-TB cohort.  Subject 
demographics and characteristics.  CA19-9 carbohydrate antigen 19-9, UCCI-TB University of 
Cincinnati Cancer Institute’s Tumor Bank, asTF alternatively spliced tissue factor.  
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Figure 3.7: Plasma CA19-9 levels and subject demographics, UCCI-TB cohort.  Correlation 
analysis, circulating asTF and CA19-9 levels.  CA19-9 carbohydrate antigen 19-9, UCCI-TB 
University of Cincinnati Cancer Institute’s Tumor Bank, asTF alternatively spliced tissue factor.  
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Chapter 4: Antibody-based targeting of 
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approach to impede the primary growth and 
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Cancer therapy is like beating the dog with a stick to get rid of his fleas. 
 
– Anna Deavere Smith 
 Let Me Down Easy 
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 4.1 Abstract 
 Alternatively spliced Tissue Factor (asTF) is a secreted form of Tissue Factor (TF) that is 
expressed in several forms of solid cancer, including pancreatic ductal adenocarcinoma (PDAC). 
asTF binds to β1 integrins on PDAC cells, whereby it promotes tumor growth, metastatic spread, 
and monocyte recruitment to the stroma.  We determined the effect of antibody-based targeting of 
asTF in PDAC would significantly impact tumor progression. We here report that asTF-β1 integrin 
interactions, when disrupted by the anti-asTF monoclonal antibody that we recently developed and 
characterized, curtail experimental PDAC progression. Moreover, we show that tumor-derived 
asTF is able to promote PDAC primary growth and spread during earlier as well as later stages of 
the disease. In addition, we show that TF expressed by host cells plays a significant role in PDAC 
spread. Together, our data demonstrate that targeting asTF in PDAC is a novel strategy to stem 
PDAC progression and spread. 
 
 
4.2 Background 
 Pancreatic ductal adenocarcinoma (PDAC) survival rate remains dismal, with 5-year 
survival <5%, and by 2020 is predicted to be the third leading cause of cancer-related death (239).  
Pancreatic cancer is commonly associated with thrombotic events, which contribute to its 
morbidity and mortality (240)(241).  Cancer coagulopathy is thought to be partially due to the up-
regulation of Tissue Factor (TF), the primary initiator of blood clotting (162)(242). Multiple 
oncogenic events that are characteristic of PDAC, e.g. activation of the proto-oncogene K-RAS 
and inactivation/loss of p53 and PTEN, promote TF expression (168).  Recently, we reported that 
TF’s secreted isoform termed alternatively spliced TF (asTF) is expressed in early-stage PDAC 
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 lesions (pancreatic intraepithelial neoplasia, PanIN) and abundant in advanced PDAC, in contrast 
to normal pancreas (229). Our groups recently demonstrated that asTF acts on cancer cells in an 
auto/paracrine manner via β1 integrins, promoting disease progression by fueling cancer cell 
proliferation, survival, metastatic spread, neovascularization, and monocyte accumulation to the 
tumor stroma (228)(229). 
 
 Unlike the much-studied major form of TF termed full-length TF (flTF), asTF is minimally 
coagulant, and triggers cellular signals through non-proteolytic mechanisms by binding to α6β1 
and αvβ3 integrins, and thereby activating PI3K/Akt, MAPK, and FAK signaling pathways (186).  
Integrin subunits α6 and β1 are up-regulated in PDAC, and play a crucial role in promoting PDAC 
aggressiveness (243).  We reported that asTF-β1 integrin interaction on endothelial cells increases 
the expression of cell adhesion molecules VCAM-1, ICAM-1, and E-selectin, which facilitates 
monocyte recruitment (194). Levels of asTF positively correlate with the number of tumor 
associated monocytes/macrophages (TAMs), which are known to significantly contribute to tumor 
progression and resistance to chemotherapy (228)(229)(244). Tumor cell-derived asTF fuels 
PDAC primary growth and spread via upregulation of various signaling pathways (229); however, 
it is not known whether host-derived TF plays a discernible role in PDAC progression.  In addition, 
it is not known whether tumor cell- and/or host-derived asTF can be targeted with a monoclonal 
antibody to stem PDAC tumor progression.   
  
 In this study, we sought to i) examine the novel asTF-integrin nexus as a potential 
therapeutic target in PDAC, including the activity of the novel asTF-specific neutralizing antibody 
RabMab1 ii) delineate the mechanisms underlying asTF-induced PDAC progression; and iii) 
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 elucidate the relative significance of host-derived TF in PDAC.  We employed a doxycycline 
(Dox)-inducible asTF transgene system to rule out the possibility of cell line and/or clonal 
selection variability influencing experimental outcomes. Using this approach, we investigated 
whether delayed-onset upregulation of asTF yields a phenotype that is distinct from that obtained 
via constitutive overexpression. The effectiveness of antibody-based targeting of asTF in PDAC 
was assessed using an orthotopic mouse model.  
 
 
4.3 Materials and methods  
4.3.1 Cell lines 
 Human PDAC cell line Pt45.P1 is classified as grade III, harbors K-RAS / p53 / p16 
mutations, and has been extensively characterized (201) / authenticated by short tandem repeat 
analysis (ATCC). A modified cell line termed Pt45.P1/asTFi was generated by permanently co-
transfecting Pt45.P1 cells with i) linearized pTet-On Advanced vector, and ii) pTRE-Tight vector 
(both from Clontech) with a human asTF expression cassette cloned into the plasmid’s multiple 
cloning site.  Fugene HD (Roche) was used to transfect the constructs; cells were maintained in 
G418 and seven G418-resistant clones were harvested, expanded, and the consistency of the levels 
of doxycycline (Dox)-inducible asTF mRNA/protein overexpression was verified before the 
clones were pooled (data not shown). All cell lines were grown in DMEM (Cellgro) supplemented 
with 10% fetal bovine serum (HyClone), 100 IU/mL penicillin, 100 µg/mL streptomycin, and 0.25 
µg/mL amphotericin at 37°C in a humidified incubator (5% CO2). 
 
4.3.2 In vivo studies 
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  All animal studies were done in compliance with the protocol approved by the Institutional 
Animal Care and Utilization Committee, University of Cincinnati. Pt45.P1/asTFi cells were 
orthotopically transplanted in the pancreases of 5-week-old female nude athymic mice, 
(n=5/cohort) (Harland Laboratories). Mice were subdivided into three cohorts: 1) animals that 
began receiving Dox (2 µg/mL in water/sucrose) on day 1 of the study (“Dox”), 2) day 25 of the 
study (“Late Dox”), and 3) sucrose water alone (“No Dox”) for 5 weeks.  Pt45.P1 cells were also 
orthotopically implanted into mice rescued from embryonic lethality caused by murine TF (Cf3) 
deficiency with a human TF (hTF) mini-gene: rescued mice (mTF-/-,hTF+/-, hereafter TF-Low) 
express only ~1% of TF levels compared to 50% expressed by their heterozygous counterparts 
(mTF+/-/hTF+/-, hereafter TF-Het) and were backcrossed into severe combined immunodeficiency 
(SCID) background (n=6/cohort) (245)(246). 
  
 In vivo efficacy studies of Rb1 were carried out as follows. Pt45.P1 cells were resuspended 
in PBS containing 100µg of Rb1 or rabbit IgG isotype control, and implanted in the pancreases of 
nude athymic / TF-Low/Het mice. Tumor progression was monitored via SapC-DOPS imaging 
over 7 weeks or when otherwise specified as previously described (n=8/cohort) (202). In brief, a 
multispectral imaging system FX (Kodak) was used to visualize tumor growth and spread 
employing Cell-Vue Maroon (CVM)-labeled, nanovesicle-coupled Saponin C protein fragment 
H2 (CVM-SapC[H2]-DOPS) injected via tail vein; this compound selectively binds to tumor cells 
as well as tumor vasculature enriched in externalized phosphatidylserine (202). Quantification of 
tumor spread was analyzed with Carestream MI software, background fluorescence normalized to 
sham-operated mice, and fluorescence was converted to photons per second per mm2. At the end 
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 of the study animals were sacrificed, necropsy was performed, and tumors were harvested and 
processed for protein, RNA, and histology (FFPE) analysis.   
 
 
4.3.3 Quantitative RT-PCR 
 Total RNA was isolated from cells / tissue flash-frozen in LN2 using the RNeasy kit 
(Qiagen) as per the manufacturer’s instructions; cDNA was synthesized using Transcriptor 
(Roche). Quantitative RT-PCR was performed using our validated TaqMan probe and primer sets 
for asTF and flTF (229); GAPDH was used as a housekeeping gene.   
 
 
4.3.4 Western blotting 
 Cells were trypsinized, washed with PBS, and pelleted. Cell pellets were resuspended in 
PBS supplemented with Protease Inhibitor I cocktail (Roche) and lysed in Laemmli buffer with 2-
Mercaptoethanol. Samples were denatured at 95°C for 10 min, loaded on 12% polyacrylamide gels 
(Life Technologies) and transferred to PVDF membranes.  Membranes were blocked overnight at 
4°C and probed with primary and corresponding HRP-conjugated secondary (Invitrogen) 
antibodies. Blots were developed using LumiLight (Roche), and chemiluminescent bands were 
visualized with X-ray film. Anti-pAkt T308 antibody (clone D25E6, Cat. No. 13038), anti-pAkt 
S473 (Cat. No. 9271), anti-total Akt (Cat. No. 9272), anti-total MAPK (Cat. No. 9102), and anti-
pMAPK p42/44 (Cat. No. 9101) were from Cell Signaling. 
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 4.3.5 Migration studies 
 Gap closure/scratch assay was performed in triplicates by seeding 12-well plates with 
Pt45.P1/asTFi cells at 1x105/well.  Doxycyclin at a concentration of 2 µg/mL was added to induce 
asTF a day before the scratch was made and the expression levels of asTF were checked by 
Western blot in the presence and absence of dox. After cells adhered and reached confluence, the 
wells of the plate were scratched at the center using a P200 pipet tip. The generated gaps were 
analyzed for closure at 0, 18, 24, 48 hours. The results were quantified using Image J software 
(NIH) by measuring the area (in pixels) that remained unoccupied at each time point.  The area at 
0 hours was set to 100%. 
 
 Transmigration assay was carried out using 24-well plates / inserts with 8.0 µm diameter 
pores (BD Bioscience) pre-coated with 50 µg/mL laminin (Sigma-Aldrich Cat# L4544) in Hank’s 
Balanced Salt Solution (HBSS; Cellgro) for 1.5 hrs.  Excess laminin was removed from the inserts, 
following which 7.5x104 Pt45.P1/asTFi cells were pre-incubated with anti-asTF antibody Rb1, 
anti-integrin β1 (R&D Systems), anti-integrin α6 (R&D Systems) or isotype control antibodies 
(Jackson ImmunoResearch) for 30 min, added to the inserts, and allowed to migrate for 5 hrs at 
37°C, 5% CO2 toward serum placed in the lower chamber. Afterwards the inserts were fixed in 
ice-cold methanol, and non-migrated Pt45.P1/asTFi cells were removed from the luminal side with 
a cotton swab. Inserts were excised, stained, and preserved with Vectashield / DAPI (Vector Labs). 
Images were captured on fluorescent microscope Keyence BZ-9000 (BIOREVO) at 20x; 6 
representative fields per insert (n=3 inserts per each condition) were captured and results were 
analyzed using Image J.  
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 4.3.6 ELISA 
 Platelet-poor murine plasma derived from whole arterial blood was assayed for asTF 
protein levels using our custom sandwich ELISA as described (232); in brief, samples were placed 
in 96-well capture plates and incubated for 3 hours at RT. Wells were washed and probed with 
asTF-specific detection antibody (Rb1) conjugated to HRP for 2 hours at RT. TMB substrate was 
then added and plate was incubated in the dark for 60 minutes; reaction was stopped with sulfuric 
acid and the plate was read at 405 nm. Serial dilutions of recombinant asTF in mouse plasma were 
used as standards in each run. 
 
 
4.3.7 Tissue harvesting and histological analyses 
 Harvested tumor specimens were fixed in formalin overnight prior to paraffin embedding. 
Paraffin embedded tumors were sectioned (4 µm), baked for 1 hour at 63°C, and rehydrated.  
Sections were placed in Antigen Retrieval Citra Solution (BioGenex) for 20 minutes in a pre-
heated steamer at 95°C; afterwards, slides were allowed to cool and rinsed in wash buffer (Dako). 
Slides were blocked for 12 min with a blocking cocktail, washed, and incubated with the primary 
antibodies: rabbit polyclonal anti-CD31 (Abcam); rabbit polyclonal anti-CD206 (abcam); 
monoclonal anti-β1 (R&D systems); monoclonal anti-α6 (R&D systems) were applied for 3 hours, 
slides washed and incubated with appropriate secondary antibodies for 30 minutes and Vectashield 
/ DAPI. Images were captured using BZ-9000 BIOREVO (Keyence) and analyzed using BZ-II 
analyzer and Image-J software. 
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 4.3.8 Statistics  
Mean values were compared using Student’s t-test between two groups, and for multiple group 
comparisons one-way ANOVA was used; p<0.05 was considered significant.  All statistical 
analyses were performed using SigmaPlot v12.5. Data are represented as the mean ± standard 
deviation.  
 
 
4.4 Results 
4.4.1 asTF-integrin interactions promote PDAC cell migration  
 We recently reported that constitutive asTF overexpression in Pt45.P1 cells promotes 
metastatic spread in vivo (229); here we sought to investigate the mechanisms responsible and 
specifically whether asTF increases cell motility. We examined the expression levels of asTF in 
Pt45.P1/asTFi cells; when treated with Dox, Pt45.P1/asTFi cells had significantly higher levels of 
asTF mRNA and protein, while flTF mRNA and protein levels remained unchanged (p<0.001) 
(Figure 4.1A & B).  Scratch assay was then performed; Dox-treated Pt45.P1/asTFi cells had 
completed gap closure by 24 hours, whereas Dox-untreated cells still had unoccupied area at 48 
hours (Figure 4.1C). asTF-integrin α6/β1 interactions are known to promote cancer cell 
proliferation (228).  To verify this enhanced scratch closure activity was due to cell migration and 
not cell proliferation, we performed a short-term cell migration analysis towards a serum chemo-
gradient using laminin-coated transmembrane inserts and Pt45.P1/asTFi cells. Laminin is 
abundantly expressed in PDAC stroma and is known to bind α6β1 integrins (247).  As in the 
scratch assay, Dox-treated cells exhibited a significantly higher migration rate compared to Dox-
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 untreated cells.  Notably, when Dox-untreated Pt45.P1/asTFi cells were pre-incubated with the 
inhibitory anti-asTF antibody RabMab1, the basal rate of their migration was significantly reduced 
(Figure 4.1D), indicating that even the relatively low basal levels of asTF constitutively expressed 
in Pt45.P1/asTFi cells significantly contribute to their migratory potential.  Pre-incubating 
Pt45.P1/asTFi Dox+ with anti-α6 inhibitory antibody yielded a partial reduction of cell migration, 
whereas pre-incubation with anti-β1 or anti-β1/anti-α6 fully inhibited cell migration (Figure 
4.1D). Thus, expression of asTF in PDAC cells enables integrin mediated onset of cellular motility, 
a hallmark of progression and metastasis. 
 
 
4.4.2 asTF promotes primary tumor growth and spread in vivo at 
early and later stages of tumor development 
 To examine the temporal effect of asTF overexpression on tumor dynamics in vivo, we 
orthotopically implanted 1x106 Pt45.P1/asTFi cells into the pancreases of nude mice (n=5/group) 
and allowed tumors to develop over a period of 5 weeks.  Mice received Dox (2µg/mL) in sucrose 
drinking water at day 1 (“Dox”), day 25 (“Late Dox”), or sucrose alone (“No Dox”), and tumor 
progression was monitored periodically in vivo using CVM-SapC[H2]-DOPS imaging (Figure 
4.2A).  At the end of the experiment, tumor growth was observed in all mice except one animal in 
the “Late-Dox” cohort. No appreciable distal  metastases was observed in the “No Dox” cohort 
compared to the other two cohorts; the macroscopic spread outside primary tumor was 
significantly reduced in “Late Dox” mice compared to “Dox” mice (p = 0.010), yet it was in-trend 
higher in “Late Dox” mice compared to “No Dox” mice (p = 0.082) (Figure 4.2A & H).  Mice 
were then euthanized and primary tumors resected and examined for weight and volume. “Dox” 
95
Antibody-based targeting of asTF: a new approach to impede the primary growth and aggressiveness of PDAC
 tumors were significantly larger in both weight and volume compared to “Late Dox” and “No 
Dox” tumors (Figure 4.2B & C).  These observations indicate that asTF expression can promote 
PDAC progression during early as well as late stages of the disease, resulting in larger tumors and 
increased spread.   
 
 
4.4.3 asTF levels are associated with changes in tumor stromal 
composition  
 Next, we compared the histology of “No Dox”, “Late Dox”, and “Dox” Pt45.P1/asTFi 
tumors for vessel density (CD31) and the levels of stromal M2-polarized tumor associated 
macrophages (TAMs) (CD206).  Both "Late Dox" and "Dox" tumors had significantly increased 
vessel density when compared to "No Dox", yet vessel density of “Late Dox” tumors was 
comparable to that of “Dox” mice; which suggests that PDAC vasculature plateaus relatively early 
during tumor development (Figure 4.2D).  In addition to "No Dox" tumors having decreased 
vessels, they also had significantly fewer TAMs, as did “Late Dox” when compared to "Dox" 
tumors (Figure 4.2E).Consistent with our in vitro asTF expression levels, histological evaluation 
of asTF showed a relative increase in "Dox" vs "No Dox" tumors, and appeared to co-localize with 
β1-integrin (Figure 4.2F).  Remarkably, asTF protein was present in circulation of mice in “Late 
Dox” as well as “Dox” cohorts at levels exceeding 1ng/mL (Figure 4.2G). Lastly, we analyzed 
the tumors for the levels of collagen deposition (Masson’s trichrome): “Late Dox” and “Dox” 
tumors had comparable collagen deposition, which was significantly higher compared to that in 
“No Dox” tumors (p=0.043) (Figure 4.2I & J).  These observations suggest that asTF has a 
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 multifaceted role in tumor stroma remodeling, whereby it increases TAMs, vessel density and 
collagen deposition.      
 
 
4.4.4 Targeting asTF with RabMab1 impedes tumor progression 
 To assess whether treatment with RabMab1 can stem the growth of PDAC cells in the 
orthotopic setting as we found to be the case for breast cancer cells (228), we co-implanted Pt45.P1 
cells with asTF inhibitory antibody RabMab1 or isotype control IgG using the same cell number 
and RabMab1 quantity that we previously employed in our breast cancer studies, i.e. 100µg/6x105 
cells, and tumor growth was monitored periodically using CVM-SapC[H2]-DOPS in vivo imaging 
over 7 weeks (n=8/cohort) (Figure 4.3A).  Tumors co-implanted with RabMab1 had a lower take 
compared to other cohorts (RabMab1: 4/8; IgG: 6/8; PBS: 7/8). Like PT45.P1/asTFi cells grown 
in mice not receiving Dox, Pt45.P1 cells did not exhibit significant spread even when grown for 7 
weeks; however, when co-implanted with RabMab1, they produced significantly smaller tumors 
(p<0.001) (Figure 4.3B & C).  RabMab1-treated tumors were also less vascularized and had ~3.5 
fold fewer stromal macrophages compared to the cells co-implanted with vehicle (PBS) and/or 
isotype control IgG (p=0.009) (Figure 4.3D & E).  Mice in the Pt45.P1/RabMab1 cohort had ~2 
fold decrease in the levels of circulating asTF compared to mice in the Pt45.P1/PBS and/or isotype 
IgG cohorts (0.27ng/mL vs 0.60/0.54 ng/mL; p<0.001).  Thus, antibody-based targeting of asTF 
may comprise a novel therapeutic strategy to stem PDAC progression. 
 
 
4.4.5 Host-TF contributes to PDAC progression  
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  We next sought to evaluate the contribution of host TF to PDAC growth and spread in our 
model using TF-Het (control) and TF-Low SCID mice.  In light of our findings in nude mice 
pointing to a limited spread of Pt45.P1 cells in the setting of 1x106 cells grown for 5 weeks (Figure 
4.2) and/or 6x105 cells grown for 7 weeks (Figure 4.3), we sought to augment the cells’ ability to 
spread in this experiment and thus orthotopically implanted 1x106 Pt45.P1 cells into TF-Low/Het 
mice and monitored tumor growth in vivo over 7 weeks. In agreement with prior studies pointing 
to SCID mice as a better platform to study the metastatic capacity of human tumor cells compared 
to nude mice (247), we observed significant systemic spread of Pt45.P1 cells in TF-Het mice 
(Figure 4.4A & D), and the fraction of mice with lung metastasis was higher in TF-Het mice than 
in TF-Low mice (4/6 vs 1/6) (Figure 4.6A & B)  Pt45.P1 tumors grown in TF-Low/Het mice were 
comparable in weight  and volume  (Figure 4.4B & 4C); however, tumor spread was significantly 
diminished in TF-Low mice (p=0.007) (Figure 4.4A & 4D).  Tumors in TF-Low mice also had 
lower vessel density (p=0.033) and had fewer M2 polarized TAMs (p=0.011) (Figure 4.4E & F).  
Notably, TF-Low tumors had decreased collagen deposition compared to TF-Het tumors 
(p=0.018) (Figure 4.4G & H). These TF-Low mice indicate that host-derived TF contributes to 
tumor spread and stromal remodeling.   
 
 
4.4.6 RabMab1 suppresses tumor growth equally in TF-Het and TF-
Low mice 
 To compare the relative contribution of tumor-derived asTF and host TF to tumor 
progression in our model, we analyzed Pt45.P1 tumor growth in TF-Low/Het mice treated with 
RabMab1 and isotype control IgG. In the presence of RabMab1, Pt45.P1 cells implanted in TF-
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 Low as well as TF-Het mice grew tumors that were significantly smaller compared to IgG control. 
We previously reported that constitutive overexpression of asTF in PT45.P1 cells induces MAPK 
and Akt phosphorylation (229); in this study, the MAPK p42/44 phosphorylation was unaffected 
by RabMab1 treatment (data not shown), yet a significant decrease in pAKT-T308 was observed 
(p=0.002), while the levels of pAKT-S473 were unaffected (Figure 4.5C). (Figure 4.5A & B) 
Moreover, RabMab1 reduced tumor vascularization and quantity of TAMs equally well in TF-Het 
and TF-Low mice (Fig 5C, 5D).   Thus, RabMab1 works equally well in stemming PDAC tumor 
growth in SCID mice, which is in agreement with our findings in nude mice.   
 
 
4.5 Discussion  
 In this study, we report the following set of novel findings: i) asTF-β1 integrin interactions 
render PDAC cells significantly more motile; ii) asTF is able to promote PDAC progression during 
early and late stages; iii) RabMab1-mediated targeting of asTF inhibits basal as well as asTF-
potentiated migration of PDAC cells; iv) host-TF contributes to PDAC spread and influences the 
stromal composition of primary PDAC tumors; v) tumor-derived asTF is a more significant 
contributor to PDAC progression compared to host-TF. 
 
 Progress in treating patients suffering from PDAC has remained relatively stagnant since 
the approval of gemcitabine in 1996. Over the last several years, different formulations and 
combinations of cytotoxic agents have improved the median survival rate by 4.4 months over 
gemcitabine monotherapy (127).  Despite these advances there remains a severe need for new 
therapeutic modalities that can target host immunity, stromal microenvironment, and cancer cell 
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 signal transduction pathways (127).  Our groups recently reported the potential for asTF to be a 
promising target in breast cancer (228); in this study, we show for the first time that inhibition of 
asTF-integrin interactions holds much promise in stemming PDAC progression.  asTF promotes 
migration of PDAC cells; we posit that asTF-β1 interactions may render PDAC cells more motile 
via asTF competing with laminin for β1 integrin binding as well as promoting outside-in integrin 
signaling. It is also possible that, as we recently described in the breast cancer setting, asTF 
modulates binding and/or migration on laminin, similarly to how flTF modulates migration on 
laminin (228); an even more intriguing scenario might be envisioned whereby asTF competitively 
blocks flTF-dependent inhibition of β1 integrins on laminin.  Our asTF-specific inhibitory 
monoclonal antibody RabMab1 inhibits basal and asTF-potentiated PDAC cell migration.  Here 
we show that, in addition to promoting tumor cell migration, asTF alters the tumor 
microenvironment by increasing the number of TAMs, vessel density, and collagen deposition.  In 
the presence of RabMab1, Pt45.P1 cells grew significantly smaller tumors with fewer TAMs, 
blood vessels, and reduced collagen content; future studies will investigate whether systemic and 
continuous administration of RabMab1, as opposed to cancer cell co-implantation, will have a 
major impact on PDAC progression: given the hypovascular, scar-like structure of desmoplastic 
PDAC tumors, antibody penetration of solid tumors remains a concern. Currently, we are defining 
the protein domain(s) of human asTF critical to its binding to β1 integrins in hope that molecular 
mapping of asTF-β1 integrin interactions will aid in the development of short inhibitory peptides 
as well as small-molecule compounds which may have superior capacity in PDAC tissue 
penetrance.  
 There is considerable interest in therapeutic targets that can attenuate aberrant signaling 
transduction pathways in PDAC. The PI3K/Akt pathway mediates a variety of cellular processes, 
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 such as cell proliferation, survival, and motility (248).  The PI3K/Akt pathway is activated in 
PDAC and is implicated in promoting resistance to apoptosis-inducing chemotherapies, and 
targeting the PI3K/Akt pathway can overcome resistance to chemotherapy (249).  Our earlier 
studies showed that asTF-integrin interactions promote AKT phosphorylation (229)(186). In our 
in vivo study of RabMab1, we observe an inhibition of the phosphorylation of Akt at T308, which 
suggests that a reduction in tumor growth and spread may be in part due to the suppression of the 
Akt-dependent pro-survival pathways.  Interestingly, we did not observe a change in the levels of 
pAkt-S473 post-treatment with RabMab1; the relative abundance of pAkt-S473 and pAkt-T308 is 
known to differ between various PDAC cell lines (250) yet no definitive information is available 
as to the relative importance of either site in PDAC pathobiology.  Still, a recent study examining 
the pAkt-S473 / pAkt-T308 status demonstrated that compared to pAkt-S473, higher 
phosphorylation of pAkt-T308 as a more reliable biomarker for smoking and alcohol induced 
progression of head-and-neck small cell carcinoma (251); we note that smoking and excessive 
alcohol consumption are the two well-established risk factors for PDAC (127).  
 
 Therapies targeting macrophage recruitment, polarization and activation may also prove 
effective therapeutic strategies based on numerous in vivo data and preclinical findings (252).  For 
multiple malignancies, high densities of TAMs are associated with poor clinical outcomes (253). 
M2-polarized TAMs, identified by mannose receptor CD206 (254)(255), but not CD68 correlate 
with negative outcome (256).  In addition to being a more selective TAM marker, CD206 is 
associated with immunosuppression and release a variety of tumor-promoting growth factors that 
correlate with poor patient prognosis (256)(257).  Here, we show that RabMab1 treatment reduces 
CD206+ TAMs in our orthotopic PDAC mouse model and decreases metastasis.  The amelioration 
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 of metastasis may in part be indirectly related to a decrease in TAMs.  Studies have demonstrated 
that M2 TAMs can promote epithelial-mesenchymal transition (254), and other in vivo tumor 
mouse models that deplete monocyte/macrophages exhibit diminished metastasis (252).  Tumor 
cell TF-induced coagulation, which results in fibrin formation, may promote premetastatic niches 
by making distal sites more receptive to growth through the recruitment of CD11b+ 
monocyte/macrophages (258).  CD11b macrophage recruitment is mediated through the binding 
of CD11b to clot components and activated endothelium (259); we previously show that asTF-
integrin interactions on microvascular endothelial cells can mediate macrophage accumulation 
independent of coagulation (194).  It remains to be determined to what extent asTF directly 
influences metastasis and how much is influenced through indirect TAM mediated metastasis.   
 
 PDAC is characterized by extensive desmoplasia and much of the tumor mass is thus 
comprised of (extra)cellular components other than cancer cells, some of which may serve as a 
“host source” of TF in the tumor microenvironment. Currently, the relative contribution of host vs 
tumor-derived TF to PDAC progression is unknown. In our study, severe depletion of host TF had 
no significant impact on primary tumor weight and/or volume; however, we did observe a 
significant decrease in vessel density and TAMs in the tumors grown in TF-Low SCID mice and 
most strikingly, the spread was also dampened in TF-Low mice. Still, inhibition of tumor derived 
asTF had a much more significant effect on PDAC progression compared to low levels of non-
tumor cell derived TF.  Our data suggests that asTF may act as an important regulator of the 
inflammatory microenvironment known to play essential role in K-RAS driven progression of 
PDAC (260).  In our hands K-RAS expressing PDAC cells exhibit low levels of TF but cooperate 
with exogenous asTF and host TF in formation of proinflammatory, prometastatic and collagen-
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 rich (desmoplastic) milieu.  It is possible that in addition to cancer cells themselves, inflammatory 
cells and blood vessels (186), asTF also regulates the activity of pancreatic stellate cells implicated 
in PDAC-related fibrosis (261), a subject of interest for our future explorations.  Since fibrosis and 
inflammation are regarded as elements of therapeutic intractability and resistance of PDAC to 
cytotoxic and targeted therapies (262), our results with the RabMab1 antibody suggests that this 
agent could act as therapeutic sensitizer in these various contexts, and possibly as a function of 
asTF detected in the circulation.   
  
 Aside from improving PDAC therapy per se, it is increasingly critical to identify reliable 
circulating biomarkers that can non-invasively determine the feasibility of surgical intervention 
(e.g. resectable/unresectable disease), or aid in patient stratification for clinical trials and/or 
therapeutic regimens. Multiple studies show that increased levels of circulating TF are associated 
with an increased risk for thrombosis in patients with cancer (263).  However, it remains to be 
determined whether circulating “total TF” is an adequate cancer biomarker with an overall 
prognostic utility.  Similar to other malignancies, PDAC exhibits aberrant pre-mRNA processing, 
which is likely to influence the relative expression of flTF and asTF. Splicing regulatory (SR) 
proteins ASF/SF2 and SRp55 are essential for biosynthesis of flTF whereas SR proteins SC35 and 
SRp40 promotes asTF biosynthesis in human monocytic cells (199)(264).  Increased expression 
of various SR proteins has been implicated in the progression of tumors of the breast (265), lung 
(266), colon (267), and ovaries (268).  Thus, it is reasonable to propose that aberrant pre-mRNA 
processing in cancer cells, including PDAC, is likely to perturb the splicing of TF pre-mRNA 
thereby increasing the levels of asTF.  Using our newly developed asTF-specific ELISA, we show 
here that asTF is detectable at high levels in the circulation of mice bearing orthotopic PDAC 
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 tumors. Importantly, RabMab1 was able to significantly reduce circulating levels of asTF to ~200 
pg/ml: recently, we reported that pre-operative circulating levels of asTF ≥200 pg/ml can help 
identify PDAC patients with a more aggressive disease (269).  We are currently conducting a 
prospective study to determine whether circulating asTF may also help in identifying recurrence 
in PDAC.       
 
 In sum, our findings show asTF-β1 integrin play a major role in pathobiology of PDAC, 
and that antibody-based targeting of asTF may comprise a novel strategy to stem PDAC 
progression.  Because asTF is i) dispensable to normal blood clotting, ii) expressed at higher levels 
in malignant tissues, and iii) able to promote tumor progression, it may very well comprise the 
preferred isoform to target in a cancer setting. 
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Figure 4.1: TF isoform expression in Pt45.P1/asTFi cells. (A) asTF/flTF mRNA expression 
levels were assessed by quantitative real-time RT-PCR (n=3). (B) Western blot, flTF/asTF 
protein levels in Pt45.P1 and Pt45.P1/asTFi cells; lysates were assessed for total protein 
concentration and volume was adjusted accordingly. (C) Quantification of gap closure / scratch 
assay, Pt45.P1/asTFi cells treated and untreated (±Dox). Bars depict the area unoccupied by 
Pt45.P1/asTFi cells (n=3) at 0, 18, 24, and 48 hours. (D) Pt45.P1/asTFi cell migration toward 
serum in a transwell assay: laminin-coated transwell inserts were seeded with Pt45.P1/asTFi cells 
treated as indicated (n=6 transwells per treatment). (RabMab1 = Rb1)   
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Figure 4.2: Growth of orthotopically implanted Pt45.P1/asTFi cells in nude mice. (A) Mice 
began receiving Dox (2µg/mL) in sucrose at day 1 of the study (“Dox”), day 25 of the study (“late 
Dox”), or sucrose alone (“No Dox”), and tumor progression were imaged by SapC-DOPS 5 
weeks post-surgery (n=5/cohort; top row, representative images). Bottom row, abdominal 
cavities of nude mice bearing orthotopic Pt45.P1/asTFi tumors. White arrow: normal pancreas; 
green outlines: tumor. Quantification of tumor weight (B) and tumor volume (C) in the three 
groups (n=5). (D) 8 view fields per specimen (n=5 per specimen type) were counted and averaged 
for vessel density as assessed by anti-CD31 staining. (E) M2 TAMs were assessed by anti-CD206 
staining. (F) Expression and co-localization of β1 integrin and asTF in tumors formed by 
Pt45P1/asTFi cells (scale bar = 20µm). (G) Plasma from mice bearing Pt45.P1/asTFi tumors was 
assayed for asTF using ELISA (n=5). (H) Quantification of tumor spread to distal sites in 
anesthetized mice via CMV-SapC-DOPS imaging. (I) Representative images, Masson’s 
Trichrome stain (scale bar = 50µm). (J) Quantification of percent area positive for Masson’s 
Trichrome stain, 5 view fields per specimen (n = 5). 
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Figure 4.3: Effects of RabMab1 on the growth of orthotopically implanted Pt45.P1 cells in 
nude mice. (A) Tumor progression was monitored in vivo via SapC-DOPS imaging over 7 weeks 
(n≥3). (B) Quantification of primary tumor weight (n≥3). (C) Representative specimens, resected 
tumors. (D) Eight view fields per specimen (n=3 per specimen type) were assessed for vessel 
density by anti-CD31 staining, and (E) for M2 TAMs by anti-Ly6C/anti-CD206 staining. (F) 
Plasma samples from each cohort bearing Pt45.P1 tumors were assayed for asTF using ELISA 
(n=3). (D) Representative images, Masson’s Trichrome stain (scale bar = 50µm). (H) 
Quantification of percent area positive for Masson’s Trichrome stain.  (RabMab1 = Rb1) 
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Figure 4.4: Contribution of host-derived TF to tumor progression, orthotopically implanted 
Pt45.P1 cells. (A) Tumor progression was monitored via CVM-SapC-DOPS (n=6).(B) 
Quantification of average primary tumor weight and (C) volume in each cohort (n=6). (D) 
Quantification of spread to distal sites. (E) Eight view fields per specimen (n=6 per specimen 
type) were assessed for vessel density by anti-CD31 staining, and (F) M2 TAMs by anti-
Ly6C/anti-CD206 staining. (G) Representative images, Masson’s Trichrome stain (scale bar = 
50µm). (H) Quantification of percent area positive for Masson’s Trichrome stain.  
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Figure 4.5: RabMab1 suppresses Pt45.P1 growth with equal efficacy in TF-Het and TF-
Low mice. (A) Average primary tumor weight, TF-Low and TF-Het SCID mice bearing 
orthotopic Pt45.P1 tumors (n≥3). (B) Average primary tumor volume (n≥3). (C) Quantification 
of vessel density as assessed by anti-CD31 staining. (D) Eight view fields per each tumor (n≥3 
per specimen type) were counted and averaged for M2 TAMs by anti-Ly6C/anti-CD206 staining. 
(E) Western blot, phosphorylation of AKT (T308 & S473) in the three cohorts; each lane is a 
sample of an individual tumor. (RabMab1 = Rb1) 
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Figure 4.6: Host-derived TF contributes to tumor spread. (A) Representative images, H&E 
stain: histology of tumors generated via orthotopic implantation of Pt45.P1 cells in the pancreases 
of SCID mice (left row), and micrometastatic lesions in the lung tissue (right row).  (B) 
Prevalence of micrometastatic lesions in the lung tissue of TF-Low and TF-Het SCID mice, H&E 
stain (n=6 mice per group).  
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Chapter 5: Discussion   
 
 
You do very nice work, young man; too bad you study an artifact 
 
 
– Yale Nemerson 
My Life with Tissue Factor  
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 5.1 Summary 
 The aim of this dissertation was to improve our understanding of the mechanisms 
regulating asTF-induced tumor progression, examine circulating levels of asTF in several disease 
conditions including PDAC, and assess the effectiveness of anti-asTF targeted therapeutics in 
hopes of improving PDAC treatment. 
  
 The work presented in chapter 2 reports that asTF expression is increased in human PDAC 
lesions, and that asTF protein expression positively correlates with the degree of vessel density 
and monocyte infiltration.  This finding is in agreement with previous reports, which show that 
asTF exhibits angiogenic activity via integrin ligation and activation of proangiogenic effector 
pathways such as FAK and AKT (186)(185).  Hobbs et al. reported that asTF expression, rather 
than flTF, induced larger more vascularized tumors in a subcutaneous pancreatic cancer model 
(185).  Van den Berg et al. subsequently reported that asTF ligates integrins α6β1 and αVβ3 on 
endothelial cells promoting angiogenesis (186).  Surprisingly, blocking FVII and thrombin, or 
deleting PAR2 was unable to abolish asTF-mediated angiogenesis, which suggests that asTF exerts 
its effects via pathways distinct from flTF.  In our model of PDAC we find that asTF promotes 
tumor spread, and show that asTF exerts autocrine/paracrine changes in PDAC cells, by eliciting 
a variety of patho(biological) processes such as EGFR signaling, angiogenesis, cell proliferation, 
EMT, cell migration, and apoptosis resistance.  One gene in particular that was highly elevated 
was EFEMP1, whose product is a ligand for EGFR and can activate MAPK and Akt promoting 
PDAC growth (206).  Studies correlate EFEMP1 levels with microvessel density in a variety of 
tumors and show that EFEMP1 promotes the expression of VEGF. 
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  Since its discovery, the role of asTF in health and disease has been highly contentious.  
Some believe that asTF behaves as a procoagulant protein, while others refute this hypothesis.  
Whether asTF behaves as a procoagulant protein appears to be highly dependent upon the 
experimental settings.  Studies measuring asTF's procoagulant potential in a setting where flTF is 
not present fails to recapitulate the biological settings of asTF - since asTF is not found in the 
absence of flTF, and thus do not take into consideration flTF/asTF synergy.  Furthermore, data 
discrepancies reproducing asTF's role in hemostasis can be attributed to the type of procoagulant 
assay being used.  Current assays for measuring asTF procoagulant potential have significant 
differences in their sensitivity and specificity.  In chapter 2 we use a sensitive and specific two-
stage activity assay to measure TF's ability to generate FXa, and show that asTF likely has a 
synergistic effect with flTF in promoting a pro-thrombotic state in PDAC:  PDAC cells that 
overexpress asTF are more procoagulant, as are the microparticles derived from these cells.  Of 
note, we observed the ability of asTF to be retained on the surface of both PDAC cells and 
microparticles.  Retention of asTF on cell and microparticle surfaces may be due to integrin 
ligation or through direct interactions with its positively charged C-terminus and anionically 
charged phospholipids.  In chapter 2 we show that asTF mediated signaling may serve as a novel 
target to treat PDAC and its thrombotic complications.       
 
 Chapter 3 examines circulating levels of asTF in patient groups known to be associated 
with increased TF and thrombosis.  Since the late 1990s when Key et al. and Giesen et al. 
demonstrated that procoagulant TF is present in blood of healthy individuals, it shifted the 
hypothesis that TF only resides in the adventitia acting as a hemostatic envelope (215)(216).  
Circulating TF has since then been reported to be elevated in DM (221), ACS (222), and pancreatic 
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 cancer (223).  Not surprisingly all of these diseases are associated with an increased risk for VTE.  
Current available assays for measuring circulating TF antigen have varying sensitivity and 
specificity (231), with some of these assays having cross-reactivity for both TF isoforms flTF and 
asTF, and thus measure 'total circulating TF'.  In chapter 3 we use a newly developed asTF specific 
ELISA to detect asTF in the plasma of healthy subjects, and patients with ongoing ACS, DM, ACS 
+ DM, and PDAC.  In this study we show circulating asTF levels ≥200 pg/mL were not 
significantly associated with either ACS and/or DM.  A few patients had remarkably high levels 
of asTF and it still remains to be definitively ascertained whether asTF is elevated in patients with 
cardiovascular disease.  However, circulating levels of asTF ≥200 pg/mL were significantly 
associated with pancreatic cancer when compared to a healthy cohort matched for age and gender.  
Pancreatic cancer patients with high asTF levels were significantly less likely to qualify for tumor 
resection.  Plasma levels of asTF were the highest in PDAC patients with distal metastases, and 
did not correlate with CA19-9 levels.  Thus, measuring asTF in plasma may help identify 
pancreatic cancer patients who have a more aggressive disease, yet have low CA19-9 levels.   
 
 Chapter 4 tests the efficacy of targeting asTF with an asTF specific monoclonal antibody 
termed RabMab1.  In chapter 2 we show that asTF influences PDAC disease progression and 
unlike the highly studied flTF, asTF triggers tumor progression via non-proteolytic mechanisms. 
asTF signals by binding α6β1 and avβ3 integrins, and thereby activating PI3K/Akt, MAPK, and 
FAK signaling pathways.  asTF-integrin signaling was shown to promote breast cancer cell 
proliferation and increase microvessel density in a xenograft model of breast cancer.  Activation 
of integrin linked signaling pathways can regulate a variety of biological processes in cancer (270), 
but they also regulate mechanical cell-cell and cell-ECM interactions.  We hypothesize that asTF-
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 integrin interactions render cells more motile by preventing integrin-ECM protein interactions.  
Using a transwell migration assay we show for the first time that asTF promotes PDAC cell 
migration, and that RabMab1 targeting of asTF-integrin interactions prevented the asTF-
potentiated migration of PDAC cells.  This study also supports the idea that asTF acts a 
proinflammatory molecule in the tumor microenvironment by increasing the levels of TAMs, 
vessel density, and collagen deposition.  Remarkably, RabMab1 was able to significantly reduce 
all these asTF-induced inflammatory effects, resulting in smaller tumors and blunted tumor spread.  
Other novel findings of this study were asTF's ability to promote tumor progression at all stages 
of the disease, and that host-derived TF contributes to PDAC spread and remodeling of tumor 
microenvironment.  Thus, antibody-based targeting of asTF may comprise a novel therapeutic 
strategy to stem PDAC progression.     
 
 
5.2 Targeting TF in cancer  
 TF plays an important role in cancer progression; multiple reports indicate that TF 
promotes cancer related coagulopathy, metastasis, tumor growth, and tumor angiogenesis. 
Currently there are a variety of very unique ways to target TF-mediated cancer progression.  One 
strategy focuses on cancer-related thrombosis.  One of the major complications of pancreatic 
cancer is the development of VTE, which is likely the result of a combination of systemic 
inflammation, procoagulant microparticles released from cancer cells, and TF expressed by cancer 
cells themselves (271).  Sproul in 1938 was the first to describe thromboembolism as a major 
complication of pancreatic cancer (272), and it was later reported that pancreatic cancer has an 
incidence rate of VTE that ranges from 17% to as high as 57% (273).  The first study to identify 
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 TF activity as the major mechanism responsible for pancreatic cancer related VTE was Silberberg 
in 1989, who showed that two PDAC cancer cell lines RWP1 and RWP2 have TF-mediated 
procoagulant activity and were able to release procoagulant microparticles (274).  These studies 
highlight the clinical relationship between TF and cancer coagulopathy, but do not answer the 
question of whether activation of coagulation can promote tumor progression, or if the increased 
procoagulant state is merely a consequence of tumor progression.   
 
 Since the “cascade” or “waterfall” theory of blood coagulation proposed almost 
simultaneously by MacFarlane, and Ratnoff in 1964 (275)(276), we have known that TF-mediated 
coagulation occurs through sequential proteolytic activation of pro-enzymes (zymogens), that 
result in the formation of fibrin.  The TF-mediated activation of coagulation results in the activation 
of clotting factors FVII, FX / FIX, and FII (prothrombin), all of which promote inflammation.  
Elevated levels of FVIIa highten the expression of C-reactive protein (CRP) and IL-6 (277).  IL-6 
was shown to play a critical role in the maintenance and progression of PanIN lesions to PDAC, 
so much so that mice expressing mutated K-RAS; which recapitulate the sequential histological 
progression of PDAC (Figure 1.2), yet had IL-6 knocked out (K-RASG12D,IL-6-/-) did not progress 
to in situ carcinoma (278).  FXa was also shown to promote the expression of CRP and IL-6 
(279)(280), and it also caused the increase in IL-8, MCP-1, and adhesion molecules ICAM, 
VCAM, and E-selectin (281).  FIIa and fibrin have very similar inflammatory responses: they both 
promote monocyte adhesion and the production of chemokine/cytokines IL-6, IL-8, and MCP-1 
(282)(283).  It was also shown that FIIa can promote tumor invasion by inducing matrix 
metalloproteinase-9 and can promote distal metastasis by making sites more receptive to growth 
of cancer cells (284)(258).  Inhibition of TF-mediated coagulation and inflammation have had 
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 varying results.  Several clinical trials that explored the effect of anticoagulation in cancer patients 
did not significantly reduce or prevent cancer progression – with the exception of prostate cancer 
that has generated conflicting results with some reports indicating a possible cancer preventative 
effect (285)(286).  The anticoagulant Warfarin inhibits the synthesis of vitamin K dependent 
clotting factors FII, FVII, FIX, and FX.  Studies examining long term use of warfarin show no 
cancer preventative effect for pancreatic cancer patients, but did show a significant increase in 
mean survival from 2.3 to 5 months, and in combination with gemcitabine to 7.1 months 
(287)(288).  Although Warfarin treatment generated only a small survival benefit, recent 
experimental evidence suggests that the non-hemostatic functions of TF may have a greater impact 
on tumor pathology and allow for targeting TF signaling without concerns of developing bleeding 
complications.   
 
 A variety of new drugs that target TF-mediated signaling pathways are being developed.  
flTF signals through PARs, which can be cleaved by the formation of either flTF:FVIIa or 
flTF:FVIIa:FXa complex (289).  Inhibition of the ternary complex with monoclonal antibody-5G9 
(mAb-5G9) prevents PAR1 signaling and coagulation activity (290).  Another inhibitor of flTF is 
mAb-10H10; and in contrast to mAb-5G9 it has minimal anticoagulant activity and inhibits PAR2 
signaling of the binary TF:FVIIa complex (291).  The generation of these two selectively inhibitory 
antibodies allows for the opportunity to address the specific roles of flTF-mediated signaling 
versus coagulation activity in tumor progression.  Surprisingly, inhibition of mAb-5G9 had no 
effect on tumor growth, but mAb-10H10 was able to significantly inhibit tumor growth in a breast 
cancer xenograft model (179).  The TF:FVIIa:PAR2 signaling nexus induces the expression of 
proangiogenic molecules and growth factors, such as VEGF, cysteine-rich angiogenic inducer 61 
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 (Cyr61), VEGF-C, CTGF, CXCL1, GM-CSF, macrophage colony-stimulating factor (M-CSF) 
and IL-8 (292)(293).  TF-PAR2 signaling promotes the expression of chemokines GM-CSF and 
M-CSF, which promote the recruitment of myeloid cells, and Gil-Bernabé et al. report that TF 
induced coagulation is responsible for macrophage recruitment and promotes tumor metastasis 
(258).  However, the results of the breast cancer xenograft studies report that flTF primarily 
promotes tumor progression via PAR2-mediated angiogenesis by promoting the expression of 
VEGF, and that blockade of downstream coagulation factors had little impact on tumor growth 
(179).  The association of flTF expression with vessel density has been reported in gliomas (294), 
lung cancer (196), breast cancer (295), colon cancer (296), liver (297), prostate  cancer (298), and 
pancreatic cancer (178).  Further highlighting the role of flTF:PAR signaling, are  genetic studies 
of mice that spontaneously develop tumors and are either PAR-1 or PAR-2 deficient.  PAR-1 
deficiency had no effect on tumor progression and in contrast PAR-2 deficiency displayed a 
decrease in tumor vessel density and had a significant decrease in tumor progression (299).  In 
light of these studies, the proteolytic signaling pathway of flTF may be an attractive therapeutic 
target by reducing angiogenesis while maintaining normal hemostasis.  However, current anti-
angiogenic drugs, such as bevacuzimab which targets VEGF and is effective in mouse xenograft 
models, but in a randomized phase III trial showed no significant benefit for progression-free 
survival, overall survival, and quality of life (300).  The results from this trial may have been due 
to a delayed therapeutic intervention and that the optimal time to intervene with antiangiogenic 
agents may be relatively early in the course of cancer.  Secondly, angiogenic pathways are 
numerous, and this redundancy can decrease the dependency on VEGF.  Moreover, PDAC tumors 
are severely desmoplastic and markedly hypovascular rendering them "sensitized" to a hypoxic 
120
Chapter 5
 environment and more likely to survive without surrounding vasculature and thus likely to be less 
vulnerable to antiangiogenic therapy.        
 
 Other potent flTF inhibitors have been developed to inhibit tumor growth.  Nematode 
anticoagulant protein c2 (NAPc2) isolated from the nematode Ancylostoma caninum is a potent 
flTF:FVIIa inhibitor that prevents the generation of FXa.  NAPc2 was shown to have antitumor 
effect in a xenograft model of colon cancer by blocking PAR-2 signaling (301), while inhibiting 
FXa with nematode anticoagulant protein 5 (NAP5) did not reduce tumor growth, thus providing 
more support to the notion that the flTF:PAR2 signaling pathway is the predominant means of 
flTF-mediated tumor progression (180). However, despite these reports a clinical study examining 
the effect of NAPc2 to treat colon cancer has been suspended (302).  It is unclear whether this 
clinical study was suspended due to bleeding complications or if NAPc2 lacked therapeutic 
benefits in the setting of colon cancer.  Despite these results, other flTF-targeting drugs are 
currently being investigated for clinical utility in stemming cancer.  These drugs are TF-inhibiting 
antibody ALT-836 and PCI-27483 (a FVIIa inhibiting molecule).  ALT-836 in combination with 
gemcitabine is currently in phase I trial to test its safety at treating locally advanced and/or 
metastatic solid tumors (303).  PCI-27483 is also being tested in combination with gemcitabine to 
treat pancreatic cancer (304).  Both of these studies are targeting the flTF-mediated PAR2 
signaling and coagulant pathways, and the results of these studies will provide very interesting 
insight on whether targeting flTF nexus will be a viable option to treat cancer.   
 
 It still remains to be determined whether flTF-targeting therapies will be useful for clinical 
applications.  One major concern for the majority of flTF therapeutics are the risk for developing 
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 bleeding complications - excluding the mAb-10H10 which targets flTF signaling without affecting 
hemostasis, but it remains to be determined if mAb-10H10 will be effective in a clinical setting.  
In 2009 van den Berg et al. discovered an alternative tumor-promoting TF-mediated mechanism 
(186).  This mechanism relies on non-proteolytic (i.e. PAR-independent) integrin-mediated 
signaling of the alternatively spliced isoform of TF (asTF).  The authors report that asTF promotes 
vessel formation via ligation of β1 and β3 integrins on endothelial cells (186).  Surprisingly, in this 
study the truncated form of flTF (i.e. the extracellular domain of flTF, see Figure 1.5) was unable 
to elicit an integrin-mediated angiogenic response.  Moreover, in this report asTF-mediated 
angiogenesis was shown to be more pro-angiogenic than flTF in an aortic sprouting assay.  Shortly 
after the discovery of asTF-integrin signaling, Srinivasan et al. reported that asTF-β1 integrins on 
microvascular endothelial cells induces the expression of cell adhesion molecules leading to 
monocyte adhesion and diapedesis (194).  Thus, in light of these reports it is easy to speculate that 
asTF-integrin signaling could fuel cancer growth and spread by increasing vessel density and 
macrophage accumulation.  In non-small cell lung cancer (NSCLC) asTF mRNA was significantly 
elevated 6.8 fold versus control, compared to only 3.4 fold increase of flTF mRNA.  Interestingly, 
asTF mRNA and not flTF mRNA levels were significantly associated with patients in stages 
IIIA/IIIB, while flTF mRNA levels had no such association (196).  Until the study by Kocatük et 
al. in 2013, the function of asTF in the tumor microenvironment was unclear (228).  The study 
reports that asTF is expressed at high levels in breast cancer tissue, and acts via β1 integrins on 
breast cancer cells to promote tumor progression via cell proliferation, resistance to apoptosis, and 
vessel density.  This study is also the first to show the efficacy of co-implantation of anti-asTF 
monoclonal inhibitor antibody RabMAb1 with breast cancer cells to reduce tumor growth (228).  
Chapter 2 of this thesis furthers our understanding of asTF-mediated tumor progression showing 
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 its ability to promote tumor metastasis and autocrine/paracrine signaling that elicits EGFR 
signaling and EMT in a PDAC setting.  Chapter 4 shows the efficacy of RabMab1 to stem PDAC 
tumor growth and spread, and adds further support to asTF-targeting as a new therapeutic option 
for TF targeted therapies.  However, much work is still needed before RabMab1 therapy can be 
brought into a clinical setting.  First, RabMab1 needs to be administered systemically by 
intravenous or intraperitoneal injections rather than co-implanted with cancer cells during 
implantation.  Also, new mouse models that recapitulate the histopathology of PDAC should be 
used - such as human PDAC-derived xenografts, to verify that RabMab1 can be effectively 
delivered to the severely desmoplastic and hypovascular tumors.  It would also be highly 
significant if RabMab1 could show synergistic effect while administered in combination with 
cytotoxic chemotherapies, such as gemcitabine.   If RabMab1 can systemically inhibit tumor 
progression using this new PDAC model and/or prove beneficial when administered with already 
clinically used cytotoxic chemotherapies, it may indeed be the preferred TF isoform to target in 
cancer since asTF is dispensable to normal hemostasis, highly expressed in malignant tissues, and 
promotes tumor progression via a variety of signaling pathways. 
 
 
5.3 Alternative pre-mRNA splicing in cancer  
 Alternative splicing is one of the primary evolutionary causes of maintaining proteome 
diversity.  It is now estimated that roughly 95% of genes are alternatively spliced in humans 
(305)(306).  Alternative splicing is a mechanism to produce multiple isoforms from a single gene 
by removing intervening sequences (introns) and joining protein coding regions (exons) through 
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 the use of alternative splice sites.  Spliced isoforms can have different functions, and in some cases 
even have antagonistic properties to the canonical isoform (307).  The plasticity afforded by 
alternative splicing greatly contributes to biological complexity, and failure to express the correct 
isoform can lead to deleterious consequences.  Alternative splicing is regulated, in part, by a family 
of splicing regulatory / serine-arginine rich (SR) proteins (308).  These proteins have an essential 
function during spliceosome assembly, which is necessary for intron removal, and their activity 
may result in either enhanced inclusion, or enhanced exclusion of an exon (309).  Exon 5 of human 
TF contains exonic splicing enhancer (ESE) motifs, recognized by SR proteins.  It was shown in 
human monocytic cells that SR proteins serine/arginine-rich splicing factor 2 (ASF/SF2) and 
splicing regulatory protein 55 (SRp55) bind to ESE motifs and promote the inclusion of exon 5, 
which results in the biosynthesis of flTF (199).  In contrast, splicing regulatory protein 40 (SRp40) 
and splicing component 35 (SC35) antagonize ASF/SF2 and SRp55 through a competitive binding 
to overlapping ESE motifs on exon 5, resulting in the exclusion of exon 5, and thus the biosynthesis 
of asTF (264).  Other studies have shown that inhibiting DNA topoisomerase I reduces the activity 
of ASF/SF2 and SRp55, leading to the reduction of flTF expression and an increase in asTF 
production by human endothelial cells (310). 
 
 Increased expression of various SR proteins promote the progression of a variety of 
malignancies, such as  breast (265), lung (266), colon (267), and ovaries (268).  However, very 
little is known about PDAC alternative pre-mRNA processing.  Hypoxia can influence alternative 
splicing by upregulating SR proteins CDC-like kinase 1 (Clk1) and CDC-like kinase 4 (Clk4), and 
inhibiting both Clk1 and Clk4, which decrease the expression of both flTF and asTF in lung cancer 
(311). Since PDAC tumors are highly hypovascular and hypoxic it is easy to speculate that PDAC 
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 cells feature aberrant alternative splicing of TF, thereby altering the levels of asTF, which is highly 
likely to influence the relative expression of flTF and asTF.  Future studies will examine whether 
there is an ‘alternative splicing switch’ that occurs during the progression of PanIN to PDAC 
disease.  If this is the case, asTF may be the preferred isoform for targeting in PDAC, a disease 
which is mainly diagnosed at later stages.  Also, new drugs are being developed that deliver anti-
tumor compounds to sites with enhanced flTF expression; since flTF is ubiquitously expressed 
throughout the body, this method will surely lack specificity.  Thus, if aberrant alternative splicing 
does occur in PDAC and since asTF is only minimally expressed in healthy tissues, it may be the 
preferred isoform to target during end-stage PDAC and/or other malignancies with aberrant 
alternative splicing.    
  
 
5.4 TF and integrin interactions in cancer    
 Integrins are heterodimeric transmembrane glycoprotein receptors that mediate cell-cell 
and cell-ECM interactions (312).  Integrins are composed of an α and β subunit.  Currently there 
are 18 α and 8 β monomer subunits that can complex with each other to form 24 integrin 
heterodimers that can bind ECM molecules such as collagens, laminins, fibronectin, and tenascin 
(270).  Integrin activity regulation is complex.  Extracellular stimuli can induce "outside-in" 
signaling, whereby integrin cytoplasmic tail act as a signal transduction platform that recruits 
kinases such as PI3K, FAK, and Src family kinases.  Outside-in signaling in turn controls cell 
attachment, migration, proliferation, and survival (247).  Integrins can also perform "inside-out" 
signaling via intracellular activators, such as talin or kindlins binding to integrin cytoplasmic tails 
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 and causing integrin extracellular conformation changes that lead to an increased affinity for 
extracellular ligands.      
 
 In 2005 Nitori et al., showed that TF expression was found to have a prognostic 
significance for determining more aggressive PDAC, and patient TF levels positively correlated 
with tumor invasiveness (176).  In this study, immunohistochemical staining revealed that TF was 
prominent at the invasive tumor front, suggesting a likely causative relationship between TF and 
tumor invasion. Integrins also localize to the leading edge of invasive tumors and regulate tumor 
invasion, thus leading to the question of whether TF and integrins interact and influence each 
other's function.  Multiple studies show that TF does indeed interact with a variety of integrins.  
Co-localization and co-imunoprecipitation studies demonstrate that TF does interact with β1-
integrins (179).  Versteeg et al. show that integrins α6β1 and α3β1 regulates flTF:PAR2 signaling 
in cancer, and that their complexation facilitated breast cancer growth (313)(299).  Surprisingly, it 
was discovered that flTF keeps β1 integrins in an inactive state and that flTF β1-integrin 
dissociation dampens flTF signaling (179).               
 
 In contrast to flTF, asTF-integrin interactions are independent of PARs and do not require 
FVIIa.  Ligation of β1 and β3 integrins by asTF promotes angiogenesis both in vitro and in vivo 
(186).  Moreover, asTF-integrin interactions prevent anoikis (a form of cell death induced by 
anchorage-dependent cells detaching from ECM) and promote proliferation of breast cancer cells 
(228).  Currently, the protein domain(s) responsible for TF-integrin association are unknown.  
Interestingly, flTF binds β1-integrins keeping them in an inactive state via its extracellular and 
intracellular domains, yet asTF binds β1 integrins and activates them.  Moreover, Van den Berg et 
126
Chapter 5
 al. show that sTF (truncated flTF) failed to evoke an angiogenic response.  This suggests that the 
unique C-terminus of asTF may be critical for activating β1-integrins. Future studies examining 
the protein domain(s) responsible for TF-mediated signaling will provide potentially valuable 
therapeutic insights for the development of new small molecule inhibitors that will disrupt TF-
integrin mediated tumor progression.   
   
 TF-integrin complex formation regulating cell migration and other tumor progression 
processes is still poorly understood.  Whether asTF influences tumor cell migration directly or 
indirectly via ECM molecules such as collagen, fibronectin, and tenascin is unknown.  Future 
studies examining how asTF regulates integrin interaction with ECM molecules would provide 
further insight into the mechanism behind asTF-mediated cell migration.  Does asTF promote 
PDAC cell migration by acting as an integrin agonist, promoting outside-in signaling and 
subsequently the activation of kinases that influence cell motility? In contrast, does asTF dampen 
inside-out signaling, by decreasing the recruitment of intracellular scaffolding proteins or, by 
binding integrins, does asTF prevent them from interacting with ECM molecules, thus allowing 
for cancer cells to escape the tumor microenvironment?  A study that examines how asTF 
influences PDAC cell transmigration through ECM molecules fibronectin, collagen, tenascin, and 
laminin would provide insight necessary to begin answering these questions.  asTF binds to α6β1 
and αvβ3 integrin heterodimers, which respectively bind laminin and fibronectin. Thus, above 
studies would allow for the identification of what ECM and integrin interactions asTF interferes 
with, thus determining whether asTF promotes migration via mechanical adhesion hindrance or 
by activating cell motility effector signaling pathways.  Furthermore, since flTF:β1-integrins 
mediate cancer signaling in breast cancer and asTF also binds β1-integrins, does asTF interact 
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 competitively with flTF to regulate β1-integrin signaling?  The interactions between integrins and 
TF play an important role in the pathobiology of TF mediated tumor progression, and future studies 
examining the mechanisms responsible will likely facilitate development of novel and useful 
strategies to stem cancer progression.        
 
 
5.5 Conclusions  
 The studies presented in this thesis demonstrate the critical role that asTF plays in cancer 
progression.  We report that asTF is abundantly expressed in human PDAC tissue, and positively 
correlates with the degree of monocyte infiltration and vessel density.  Tumor cells that express 
asTF have increased tumor metastasis to distal sites in vivo in an orthotopic mouse model of 
PDAC; in vitro, asTF-β1 integrin interaction renders PDAC cells more motile, and importantly, 
targeting asTF with an inhibitory antibody RabMab1 can inhibit asTF mediated cell migration.  In 
our PDAC orthotopic mouse model, asTF was shown to have a synergistic effect with flTF by 
increasing the procoagulant potential when expressed in combination with flTF.  Unlike flTF, asTF 
is secreted and can exert autocrine/paracrine effects on PDAC cells resulting in global changes in 
gene expression implicated in EMT, apoptosis resistance, cell proliferation, and metastatic spread.  
When RabMab1 is co-implanted with PDAC cells into mice, tumor size was significantly reduced 
with fewer macrophages and blood vessels, and had a reduction in tumor spread.  Thus, antibody-
based targeting of asTF may comprise a novel therapeutic strategy to stem PDAC progression as 
well as its thrombotic complications.    
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  In plasma samples of tumor bearing mice, we were able to detect circulating levels of asTF 
protein, and when tumor cells were treated with RabMab1, a significant decrease in circulating 
asTF was observed.  We then analyzed plasma of PDAC patients for asTF levels, and found a 
significant increase in the number of patients who had elevated plasma asTF versus a healthy age 
and sex matched cohort.  Surprisingly, PDAC patients whose asTF levels were greater than or 
equal to 200 pg/mL had a significantly lower chance to qualify for tumor resection.  Thus, asTF 
may also comprise a novel marker of aggressive PDAC phenotype with a potential utility in patient 
stratification, warranting prospective evaluation of larger PDAC patient cohorts.   
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